STOCK TITAN

TOMI Environmental proposes authorizing 10M preferred shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
PRE 14A

Rhea-AI Filing Summary

TOMI Environmental Solutions, Inc. (TOMZ) is asking shareholders to vote at its virtual-only annual meeting on December 18, 2026. The ballot includes Halden S. Shane’s election as a Class III director for a three-year term, ratification of Rosenberg Rich Baker Berman & Co. as auditor for 2026, an advisory executive-pay vote, a 2026 equity plan reserving 3,500,000 common shares, and charter amendments to authorize 10,000,000 blank-check preferred shares and let the Board establish or modify meeting quorum, subject to applicable law and exchange rules. The Board recommends “FOR” each proposal.

As of November 10, 2026, 10,022,232 common shares and 21,250 Series A preferred shares were outstanding, each with one vote; at least 5,021,742 shares must be represented for a quorum. The meeting is online only, with voting and questions available through the webcast. In 2025, approximately $476,000 of salary earned by CEO and Chairman Halden S. Shane and COO Elissa J. Shane was not paid in cash and was accrued. The company intends to satisfy these obligations as operating cash flow permits.

Equity plan share reservation 3,500,000 common shares Proposed 2026 Equity Incentive Plan
Preferred-stock authorization 10,000,000 shares Proposed charter amendment for blank-check preferred stock
Common shares outstanding 10,022,232 shares As of November 10, 2026; one vote per share
Series A preferred shares outstanding 21,250 shares As of November 10, 2026; one vote per share
Quorum threshold 5,021,742 shares Shares of Voting Stock required to be present or represented by proxy
Accrued unpaid executive salaries Approximately $476,000 2025 salary earned by Halden S. Shane and Elissa J. Shane; accrued as of December 31, 2025
Halden S. Shane beneficial voting power 13.6% As of November 2, 2026
blank check preferred stock technical
"authorize 10,000,000 shares of “blank check” preferred stock"
broker non-vote regulatory
"What is a “broker non-vote”?"
A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.
plurality of votes cast regulatory
"Plurality of Votes Cast"
beneficial owner financial
"the “beneficial owner” of shares held in “street name”"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
restricted stock units financial
"100,000 restricted stock units under the 2016 Equity Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What proposals are on the 2026 TOMZ annual meeting ballot?

Shareholders will vote on Halden S. Shane’s election as a Class III director, auditor ratification, an advisory executive-compensation vote, the 2026 Equity Incentive Plan, and amendments on preferred-stock authorization and meeting quorum. The Board recommends voting “FOR” each proposal.

How can shareholders attend the TOMZ 2026 annual meeting?

The meeting will be held online on December 18, 2026, at 1:00 p.m. Eastern Time, at https://www.cstproxy.com/tomimist/2026. Shareholders need the control number on their proxy card to log in, vote, and submit questions; in-person attendance is not available.

How many shares are needed for a quorum at the TOMZ 2026 annual meeting?

At least 5,021,742 shares of Voting Stock must be present or represented by proxy to constitute a quorum. Abstentions and broker non-votes count as present for determining whether a quorum exists.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

 

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

☒

Preliminary Proxy Statement

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐

Definitive Proxy Statement

☐

Definitive Additional Materials

☐

Soliciting Material Pursuant to §240.14a-12

 

 TOMI ENVIRONMENTAL SOLUTIONS, INC.

(Name of Registrant as Specified in Its Charter)

 

Not Applicable

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

☒

No fee required.

☐

Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

(1)

Title of each class of securities to which transaction applies:

(2)

Aggregate number of securities to which transaction applies:

(3)

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)

Proposed maximum aggregate value of transaction:

(5)

Total fee paid:

☐

Fee paid previously with preliminary materials.

☐

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)

Amount Previously Paid:

(2)

Form, Schedule or Registration Statement No.:

(3)

Filing Party:

(4)

Date Filed:

 

 

 

  

GRAPHIC

 

8430 Spires Way

 

Frederick, Maryland 21701

 

November [●], 2026

 

Dear Shareholder:

 

You are cordially invited to attend the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of TOMI Environmental Solutions, Inc., which will be conducted in a virtual-only format on Friday, December 18, 2026, at 1:00 p.m., Eastern Time. You may participate in the Annual Meeting if you were a shareholder as of the close of business on Tuesday, November 10, 2026 or you hold a valid proxy for the meeting.

 

The Annual Meeting will be conducted in a virtual-only format via live webcast. Shareholders or their proxies can participate in, and vote at, and ask questions during the Annual Meeting by visiting https://www.cstproxy.com/tomimist/2026 and logging in with your voter control number shown on the accompanying proxy card.

 

We will continue to hold the Annual Meeting virtually in an effort to ensure that more shareholders can attend the meeting. You will not be able to attend the Annual Meeting in person. We also look forward to answering questions from shareholders at the end of the meeting. Accompanying this letter is a Notice of Annual Meeting of Shareholders and related proxy statement describing the business to be conducted at the Annual Meeting.

 

Your vote is important to us and whether or not you plan to join us for the Annual Meeting, it is important that your shares be represented. We encourage you to vote in advance of the meeting, which you can do either by marking, signing, and dating the accompanying proxy card and returning it to us using the enclosed postage-paid envelope, or by visiting the website shown on the accompanying proxy card and voting via the Internet.

 

On behalf of the Board of Directors, thank you for your continued support of TOMI.

 

Sincerely,

 

/s/ Halden S. Shane

Dr. Halden S. Shane

Chairman of the Board

 

 

 

 

GRAPHIC

 

NOTICE OF ANNUAL MEETING OF SHAREHOLDERS

To Be Held Virtually at 1:00 p.m., Eastern Time, on Friday, December 18, 2026

 

The 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of TOMI Environmental Solutions, Inc., a Florida corporation (“TOMI,” the “Company” or “we”), which will be conducted in a virtual-only format on Friday, December 18, 2026, at 1:00 p.m., Eastern Time. You will not be able to attend the virtual Annual Meeting in person. Shareholders of record and beneficial owners of our common stock will be able to participate in the meeting, vote, and submit questions during the meeting via live webcast by visiting https://www.cstproxy.com/tomimist/2026. To participate in the meeting, you must have your control number that is shown on your proxy card. The Annual Meeting is being held for the purpose of considering and acting upon the following proposals:

 

1.

to elect the director nominee named in the accompanying proxy statement to serve on our Board of Directors as a Class III director for a three-year term that will expire at our 2029 annual meeting of shareholders (Proposal 1);

 

 

2.

to ratify, on a non-binding, advisory basis, the selection of Rosenberg Rich Baker Berman & Co. as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 2);

 

 

3.

to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (Proposal 3);

 

 

4.

to approve the TOMI Environmental Solutions, Inc. 2026 Equity Incentive Plan (the “2026 Equity Incentive Plan”), including the reservation of 3,500,000 shares of Common Stock for issuance thereunder (Proposal 4);

 

 

5.

to approve an amendment to the Company’s Articles of Incorporation to:

 

 

 

- authorize 10,000,000 shares of “blank check” preferred stock (Proposal 5A); and

 

 

 

- authorize the Board of Directors to establish and modify the quorum for shareholder meetings, from time to time and subject to applicable law and securities exchange rules (Proposal 5B).

 

To consider and act upon other business that may properly come before the Annual Meeting and any postponements or adjournments thereof.

 

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE ELECTION OF THE CLASS III DIRECTOR NOMINEE LISTED IN PROPOSAL 1, “FOR” PROPOSAL 2, “FOR” PROPOSAL 3, “FOR” PROPOSAL 4, “FOR” PROPOSAL 5A, AND “FOR” PROPOSAL 5B.

 

The Board of Directors has fixed the close of business on Tuesday, November 10, 2026, as the record date (the “Record Date”) for determining the holders of our common stock and our cumulative $0.01 series A preferred stock entitled to notice of and to vote at the Annual Meeting and any postponements or adjournments thereof. Only shareholders of record at the close of business on the Record Date are entitled to vote, virtually or by proxy, at the Annual Meeting.

 

The proposals referred to above are more fully described in the accompanying proxy statement. An annual report to shareholders outlining our operations during the fiscal year ended December 31, 2025, accompanies this Notice of Annual Meeting of Shareholders and the accompanying proxy statement.

 

Your vote is important. All shareholders are invited to virtually attend the Annual Meeting by visiting https://www.cstproxy.com/tomimist/2026. Our goal is to ensure that shareholders have the same rights and opportunities to participate in the Annual Meeting as you would at an in-person meeting. You will be able to attend the meeting online, vote your shares electronically, and submit questions during the meeting. To do so, you will need the unique 12-digit control number printed on your proxy card. Additional information on how you can participate in the Annual Meeting to the fullest extent is set forth in the accompanying proxy statement in the section titled “Questions and Answers About the Virtual Annual Meeting and Voting,” beginning on page 1 thereof.

 

Regardless of whether you expect to attend the meeting, your vote is important to us and your shares should be represented at the Annual Meeting. Accordingly, we encourage you to vote in advance of the meeting, which you can do either by marking, signing and dating the accompanying proxy card and returning it to us using the enclosed postage-paid envelope, or by visiting the website shown on the accompanying proxy card and voting via the Internet.

 

BY ORDER OF THE BOARD OF DIRECTORS,

 

/s/ Halden S. Shane

Dr. Halden S. Shane

Chief Executive Officer and Chairman of the Board

Frederick, Maryland

November [●], 2026

 

 

 

 

TABLE OF CONTENTS

 

 

Page

PROXY STATEMENT

1

QUESTIONS AND ANSWERS ABOUT THE VIRTUAL ANNUAL MEETING AND VOTING

2

PROPOSAL 1: ELECTION OF CLASS III DIRECTOR

9

INFORMATION ABOUT THE CLASS III DIRECTOR NOMINEE

9

CONTINUING DIRECTORS

10

CORPORATE GOVERNANCE

12

DELINQUENT SECTION 16(a) REPORTS

17

REPORT OF THE AUDIT COMMITTEE

17

NON-EMPLOYEE DIRECTOR COMPENSATION

18

INFORMATION REGARDING OUR EXECUTIVE OFFICERS

19

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

20

EXECUTIVE COMPENSATION

21

OUTSTANDING EQUITY AWARDS AT 2025 FISCAL YEAR-END

23

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

25

EQUITY COMPENSATION PLAN INFORMATION

25

PAY VERSUS PERFORMANCE

26

PROPOSAL 2: RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

28

PROPOSAL 3: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION

30

PROPOSAL 4: APPROVAL OF TOMI ENVIRONMENTAL SOLUTIONS INC. 2026 EQUITY INCENTIVE PLAN

31

PROPOSAL 5A: APPROVAL OF PREFERRED STOCK CHARTER AMENDMENT

40

PROPOSAL 5B: APPROVAL OF QUORUM CHARTER AMENDMENT

41

OTHER MATTERS

42

SHAREHOLDER PROPOSALS FOR 2027 ANNUAL MEETING

42

DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS

43

IMPORTANT

43

APPENDIX A – TOMI ENVIRONMENTAL SOLUTIONS INC. 2026 EQUITY INCENTIVE PLAN

A-1

APPENDIX B – ARTICLES OF AMENDMENT TO ARTICLES OF INCORPORATION

B-1

 

 

Table of Contents

 

TOMI ENVIRONMENTAL SOLUTIONS, INC.

 

PROXY STATEMENT

 

2026 ANNUAL MEETING OF SHAREHOLDERS

To Be Held Virtually at 1:00 p.m., Eastern Time, on Friday, December 18, 2026

 

The enclosed proxy is furnished in connection with the solicitation of proxies by the board of directors (the “Board of Directors” or “Board”) of TOMI Environmental Solutions, Inc., a Florida corporation (“TOMI,” the “Company,” “we,” “us” or “our”), for use at the virtual 2026 annual meeting of shareholders (the “Annual Meeting”) to be held virtually at 1:00 p.m., Eastern Time, on Friday, December 18, 2026, or at any postponements or adjournments of the Annual Meeting, for the purposes set forth in this proxy statement (this “Proxy Statement”) and in the accompanying Notice of Annual Meeting of Shareholders.

 

We are providing these materials to holders of record of our common stock, $0.01 par value per share (the “Common Stock”), and/or our cumulative $0.01 series A preferred stock, $0.01 par value per share (“Series A Preferred Stock” and, together with the Common Stock, “Voting Stock”), at 5:00 p.m., Eastern Time, on Tuesday, November 10, 2026 (the “Record Date”) and are first mailing the proxy materials on or about November [●], 2026.

 

The Annual Meeting will be conducted in a virtual-only format via live webcast, which you can access by visiting https://www.cstproxy.com/tomimist/2026 and logging in with your voter control number, which may be found on your accompanying proxy card.

 

 
1

Table of Contents

 

QUESTIONS AND ANSWERS ABOUT THE VIRTUAL ANNUAL MEETING AND VOTING

 

The following questions and answers are intended to briefly address potential questions that our shareholders may have regarding this Proxy Statement and the Annual Meeting. They are also intended to provide our shareholders with certain information that is required to be provided under the rules and regulations of the Securities and Exchange Commission (the “SEC”). These questions and answers may not address all of the questions that are important to you as a shareholder. If you have additional questions about the proxy materials, Proxy Statement or the Annual Meeting, please see the section titled “Whom should I contact with other questions?” below.

 

Why am I receiving these materials?

 

We are providing this Proxy Statement and the accompanying proxy materials in connection with the solicitation by the Board of proxies to be voted at the Annual Meeting. You received these materials because you held shares of our Voting Stock on the Record Date and are entitled to vote at the Annual Meeting. This Proxy Statement contains important information for you to consider when deciding how to vote on the matters brought before the Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement. However, you do not need to virtually attend the Annual Meeting to vote your shares of Voting Stock. Instead, you may vote your shares using one of the other voting methods described in this Proxy Statement. Regardless of whether you expect to attend the Annual Meeting, please vote your shares as soon as possible in order to ensure your representation at the Annual Meeting.

 

What is the purpose of the Annual Meeting?

 

At the Annual Meeting, our shareholders will be asked to consider and vote upon the matters described in this Proxy Statement and any other matters that properly come before the Annual Meeting.

 

When and where will the Annual Meeting be held?

 

The Annual Meeting will be held in a virtual-only format via live webcast at 1:00 p.m., Eastern Time on Friday, December 18, 2026. Shareholders of record, and beneficial owners of our Voting Stock who are register for the meeting in advance, will be able to participate in, and vote at, and ask questions during the Annual Meeting by visiting https://www.cstproxy.com/tomimist/2026 and logging in with your voter control number, which may be found on your accompanying proxy card.

 

Why is the Annual Meeting being held virtually?

 

The Annual Meeting is being held in a virtual-only format in order to enable participation by the broadest number of shareholders possible, and to save costs compared to a physical meeting. We also believe that a virtual format will enable shareholders to participate in the Annual Meeting more easily.

 

What if I have technical or other “IT” problems logging into or participating during the Annual Meeting webcast?

 

We have established a toll-free technical support “help line” that can be accessed by any shareholder who experiences any problems logging into or participating during the Annual Meeting. If you encounter any difficulties accessing the Annual Meeting during the check-in or meeting time, please call the toll-free telephone number that will be shown on the login page for the Annual Meeting and a member of the technical support team will assist you.

 

How can I participate and ask questions at the Annual Meeting?

 

We are committed to ensuring that our shareholders have substantially the same opportunities to participate in the Annual Meeting as they would have at an in-person meeting. In order to submit a question at the Annual Meeting, you will need to login to the webcast using your control number, which may be found on your accompanying proxy card. Once you are logged in, you may submit questions online before and during the Annual Meeting. We encourage you to submit any question that is relevant to the business of the meeting. All germane and appropriate questions asked during the Annual Meeting will be read and addressed during the meeting. Shareholders are encouraged to login to the webcast at least 15 minutes prior to the scheduled start time of the Annual Meeting to test their internet connectivity.

 

 
2

Table of Contents

 

How do I attend the Annual Meeting?

 

As a shareholder of record, you received a proxy card from Continental Stock Transfer & Trust (“Continental Stock Transfer”). The proxy card contains instructions on how to attend the Annual Meeting including the URL address, along with your control number. You will need your control number for access. If you do not have your control number, contact our transfer agent, Continental Stock Transfer, by phone at (917) 262-2373, or email at proxy@continentalstock.com.

 

You can pre-register to attend the virtual meeting starting December 4, 2026 at 9:00 a.m. Eastern Time. To pre-register, enter https://www.cstproxy.com/tomimist/2026 into your browser and enter your control number, name and email address. Once you pre-register, you can vote or enter questions in the chat box. At the start of the meeting, you will need to re-login using your control number.

 

Beneficial owners, who own their investments through a bank or broker, will need to contact Continental Stock Transfer to receive a control number. If you plan to vote at the Annual Meeting, you will need to have a legal proxy from your bank or broker, or if you would like to join and not vote, Continental Stock Transfer will issue you a guest control number with proof of ownership. In either case, you must contact Continental Stock Transfer for specific instructions on how to receive the control number. Continental Stock Transfer may be contacted at the number or email address above. Please allow up to 72 hours prior to the meeting for processing your control number.

 

If you do not have internet capabilities, you can listen to the meeting by dialing (800) 450-7155 (toll-free), or outside the U.S. and Canada +1 (857) 999-9155 (standard rates apply), and, when prompted, entering the pin number 8201812#. Calling this line will not allow you to vote or enter questions during the meeting.

 

What is a “proxy”?

 

The term “proxy,” when used with respect to a shareholder, refers to either a person or persons legally authorized to act on the shareholder’s behalf or a format that allows the shareholder to vote without attending the Annual Meeting. Because it is important that as many shareholders as possible be represented at the Annual Meeting, the Board is asking that you review this Proxy Statement carefully and then vote by following the instructions set forth on your accompanying proxy card. In voting prior to the Annual Meeting, you will deliver your proxy to Elissa J. Shane (the “Proxy Holder”), which means you will authorize Ms. Shane, as the Proxy Holder, or her respective designee, to vote your shares at the Annual Meeting in the way you instruct. All shares represented by valid proxies will be voted in accordance with the shareholder’s specific instructions.

 

What proposals will be voted on at the Annual Meeting?

 

Shareholders will vote on the following proposals at the Annual Meeting:

 

1.

to elect the director nominee named in this Proxy Statement to serve on the Board as a Class III director for a three-year term that will expire at our 2029 annual meeting of shareholders (Proposal 1);

 

 

2.

to ratify, on a non-binding, advisory basis, the selection of Rosenberg Rich Baker Berman & Co. as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 2);

 

 

3.

to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (Proposal 3); and

 

 

4.

to approve the TOMI Environmental Solutions, Inc. 2026 Equity Incentive Plan (the “2026 Equity Incentive Plan”), including the reservation of 3,500,000 shares of Common Stock for issuance thereunder (Proposal 4);

 

 

5. 

to approve an amendment to the Company’s Articles of Incorporation to

 

 

 

- authorize 10,000,000 shares of “blank check” preferred stock (the “Preferred Stock Charter Amendment”) (Proposal 5A); and

 

 

 

- authorize the Board of Directors to establish and modify the quorum for shareholder meetings, from time to time and subject to applicable law and securities exchange rules (the “Quorum Charter Amendment”) (Proposal 5B)

 

To consider and act upon other business that may properly come before the Annual Meeting and any postponements or adjournments thereof.

 

 
3

Table of Contents

 

What if another matter is brought before the meeting?

 

The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matter is properly brought before the Annual Meeting, your signed proxy card will authorize the Proxy Holder to vote on such matters in accordance with his or her best judgment.

 

Who is entitled to vote at the Annual Meeting?

 

Shareholders of record at 5:00 p.m., Eastern Time, on the Record Date will be entitled to vote at the Annual Meeting. As of the Record Date, there were 10,022,232 shares of our Common Stock and 21,250 shares of our Series A Preferred Stock outstanding, each of which is entitled to one vote on each matter submitted to shareholders at the Annual Meeting. Shareholders are not entitled to cumulative voting rights in the election of directors. As a result, up to a total of 10,043,482 votes can be cast on each matter presented for consideration at the Annual Meeting.

 

 

What does it mean to be a “shareholder of record”?

 

If, at 5:00 p.m., Eastern Time, on the Record Date, your shares were registered directly in your name with our transfer agent, Continental Stock Transfer, then you are a “shareholder of record.” As a “shareholder of record,” you may vote at the Annual Meeting or vote by proxy. Regardless of whether you plan to attend the Annual Meeting, we urge you to vote your shares using one of the voting methods described in this Proxy Statement and the accompanying proxy card.

 

What does it mean to be a “beneficial owner” of shares held in “street name”?

 

If, at 5:00 p.m., Eastern Time, on the Record Date, your shares of Voting Stock were held in an account at a broker, bank, or other financial institution (we refer to each of those organizations as a “broker”), then you are the “beneficial owner” of shares held in “street name” and these proxy materials are being made available to you by that broker. The broker holding your account is considered the shareholder of record for purposes of voting at the Annual Meeting. You have the right to direct your broker on how to vote the shares in your account by following the instructions printed on the voting instruction form received from the broker holding such shares.

 

How do I vote if my shares are held in “street name”?

 

If your shares of Voting Stock are held in “street name,” you will need to contact Continental Stock Transfer to receive a control number. You may contact Continental Stock Transfer by phone at (917) 262-2373, or email at proxy@continentalstock.com.

 

If I hold my shares in street name and fail to provide specific voting instructions to the bank, broker or other institution holding such shares on my behalf, will my shares still get voted?

 

Not on all matters. If you hold your shares of Voting Stock in street name and want a vote to be cast on your behalf for all proposals described in this Proxy Statement, you must submit your specific voting instructions to the bank, broker or other institution holding such shares on your behalf in response to the voting instruction form you receive from such broker.

 

What is a “broker non-vote”?

 

A “broker non-vote” occurs when shares held by a broker in “street name” for a beneficial owner are not voted with respect to a proposal because (i) the broker has not received voting instructions from the shareholder who beneficially owns such shares and (ii) the broker lacks the authority to vote such shares at its discretion.

 

 
4

Table of Contents

 

Under applicable rules, brokers do not have the authority to elect the director nominee to serve on the Board as a Class III director (Proposal 1), approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (Proposal 3), approve the 2026 Equity Incentive Plan (Proposal 4), approve the Preferred Stock Charter Amendment (Proposal 5A), or approve the Quorum Charter Amendment (Proposal 5B). As such, a broker may not vote your shares with respect to such proposals, or any other non-discretionary (or non-routine) matters, without your instructions. If your shares are held of record by a broker, we urge you to give instructions to your broker as to how you wish your shares to be voted so you may participate in the shareholder voting on these important matters.

 

The ratification of appointment of Rosenberg Rich Baker Berman & Co. as our independent registered public accounting firm for the year ending December 31, 2026 (Proposal 2) is considered a discretionary (or routine) matter under applicable stock exchange rules. A broker, bank, or other nominee may generally vote on such routine matters, and therefore we do not expect broker non-votes in connection with Proposal 2.

 

What is the quorum requirement?

 

A quorum of shareholders is necessary to hold a valid meeting and transact business. A quorum will be present at the Annual Meeting if shareholders holding shares of Voting Stock representing a majority of the votes entitled to be cast at the Annual Meeting are present or represented by proxy at the Annual Meeting. On the Record Date, there were 10,043,482 shares of our Voting Stock outstanding, each of which is entitled to one vote on each matter submitted to shareholders at the Annual Meeting. As such, shareholders holding at least 5,021,742 shares of Voting Stock must be present or represented by proxy at the Annual Meeting in order to constitute a quorum.

 

We count proxies marked “WITHHOLD AUTHORITY,” as to any director nominee, or “ABSTAIN,” as to any other proposal, for purposes of determining the presence or absence of a quorum at the Annual Meeting for the transaction of business. Abstentions and broker non-votes will be treated as shares that are present and entitled to vote for purposes of determining the presence of a quorum. If a quorum is not present, the Annual Meeting may be adjourned from time to time until a quorum is obtained.

 

How do I vote my shares?

 

Shareholders of record can vote by proxy or by attending the Annual Meeting and voting, each of which method is further described below. If you elect to vote by proxy, you can do so via the Internet or by mail, and your shares will be voted by the Proxy Holder.

 

·

Voting by Internet. If you are a registered shareholder, you may use the Internet to vote your proxy 24 hours a day, 7 days a week. Have your proxy card in hand when you log on and follow the instructions included with your accompanying proxy card. You are encouraged to vote electronically via the Internet. If you vote via the Internet, you do not need to return a proxy card. If your shares are held in “street name,” please follow the instructions provided on your accompanying proxy card or the voting instruction card provided to you by your broker, bank or other nominee, as applicable, to determine whether you will be able to vote via the Internet. If you need assistance in revoking your proxy or changing your vote, please contact our investor relations department either by telephone at (800) 525-1698 or by email to info@tomimist.com.

 

 

·

Voting by Mail. To vote by mail, please sign, date and return to us as soon as possible the enclosed proxy card. An envelope with postage paid, if mailed in the United States, is provided for this purpose. Properly executed proxies that are received in time and not subsequently revoked will be voted by the Proxy Holder as instructed on such proxies. If you vote via the Internet as described above, you need not also mail a proxy to us.

 

 

·

Voting at the Annual Meeting. If you are a shareholder of record, you may attend the Annual Meeting and vote and submit questions during the meeting via the virtual meeting website located at https://www.cstproxy.com/tomimist/2026. Instructions on how to attend and participate via the Internet are included in this Proxy Statement and the accompanying materials.

 

 
5

Table of Contents

 

YOUR VOTE IS IMPORTANT. We encourage you to vote online or submit your proxy even if you plan to attend the Annual Meeting, so that your vote will be counted in the event you later decide not to attend the Annual Meeting. The method you use to vote will not limit your right to vote at the Annual Meeting if you decide to attend the virtual Annual Meeting. If you are the beneficial owner of shares of Voting Stock held in “street name,” you must obtain a legal proxy, executed in your favor by your broker, bank or other nominee, in order to vote at the Annual Meeting, and you should refer to the information provided by your broker to see which voting options are available to you and to see what steps you must follow if you choose to attend the virtual Annual Meeting to vote your shares.

 

Can I revoke a previously delivered proxy or change my vote after I deliver my proxy?

 

Yes. You may revoke a previously delivered proxy by delivering another properly completed proxy with a later date (including any subsequent proxy delivered via the Internet) or by delivering written notice of revocation of your proxy to TOMI Environmental Solutions, Inc., 8430 Spires Way, Frederick, Maryland 21701, Attention: Corporate Secretary, in each case, before the exercise of the previously delivered proxy at the Annual Meeting. You may also revoke your proxy by participating in and voting your shares the virtual Annual Meeting. Attending the virtual Annual Meeting will not by itself cause your previously granted proxy to be revoked. If you are a beneficial owner of shares held in street name, you should contact your bank, broker or other nominee for instructions as to whether, and how, you can change or revoke your proxy.

 

What vote is required to approve the Proposals?

 

Assuming the presence of a quorum at the Annual Meeting:

 

Proposal

Voting Standard

Effect of Abstention/Withholding

Effect of Broker Non-Votes

Proposal 1:

Election of Class III directors

Plurality of Votes Cast

No Effect

No Effect

Proposal 2:

Ratification of the appointment of Rosenberg Rich Baker Berman & Co. as our independent registered public accounting firm

Majority of Votes Cast

No Effect

Your broker, bank or nominee

may vote in its discretion

Proposal 3:

Approval of, on a non-binding, advisory basis, the compensation of the Company’s named executive officers

Majority of Votes Cast

No Effect

No Effect

Proposal 4:

Approval of the 2026 Equity Incentive Plan

Majority of Votes Cast

No Effect

No Effect

Proposal 5A:

Approval of the Preferred Stock Charter Amendment

Majority of Votes Cast

No Effect

No Effect

Proposal 5B:

Approval of the Quorum Charter Amendment

Majority of Votes Cast

No Effect

No Effect

 

Assuming a quorum is present, directors shall be elected (Proposal 1) by a plurality of the votes cast by the shareholders present in person (virtually) or represented by proxy at the meeting and entitled to vote on the election of directors. Therefore, the director nominee that receive the greatest affirmative votes cast shall be elected as directors. We do not have cumulative voting rights for the election of directors.

 

The proposals to ratify Rosenberg Rich Baker Berman & Co. as the independent registered public accounting firm of our Company for the year ending December 31, 2026 (Proposal 2), to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (Proposal 3), to approve the 2026 Equity Incentive Plan (Proposal 4), to approve the Preferred Stock Charter Amendment (Proposal 5A), and to approve the Quorum Charter Amendment (Proposal 5B) shall each be decided by the affirmative vote of a majority of the votes cast by the shareholders present in person (virtually) or represented by proxy at the meeting.

 

 

The vote on each matter submitted to shareholders will be tabulated separately. A representative of Continental Stock Transfer will tabulate the votes.

 

 
6

Table of Contents

 

Broker Non-Votes and Abstentions

 

For purposes of Proposal 1, proxies marked “WITHHOLD AUTHORITY” with respect to the election of one or more directors will not be voted with respect to the director or directors indicated and, as such, will not have an effect in determining the election results. Similarly, abstentions will have “NO EFFECT” on the outcome of Proposal 1.

 

Proposals 2, 3, 4, 5A, and 5B will each require the affirmative vote of a majority of the votes cast by the shareholders present in person (virtually) or represented by proxy at the meeting on such proposals. Abstentions will be counted toward the tabulation of votes present or represented by proxy on this proposal, and will have “NO EFFECT” on the outcomes of Proposals 2, 3, 4, 5A, and 5B.

 

Proposals 1, 3, 4, 5A, and 5B are expected to be “non-discretionary” (non-routine) matters under applicable stock exchange rules, meaning that if you are the beneficial owner of your shares and do not instruct your broker how to vote with respect to such proposals, your broker is not permitted to vote on such proposals and your votes will be counted as broker non-votes. Broker non-votes will have “NO EFFECT” in determining the outcomes of Proposals 1, 3, 4, 5A, and 5B.

 

Proposal 2 is expected to be a “discretionary” (routine) matter under applicable stock exchange rules, meaning that if you are the beneficial owner of your shares and do not instruct your broker how to vote with respect to Proposal 2, your broker may use its discretion to vote your uninstructed shares on Proposal 2. As such, we do not expect any broker non-votes for Proposal 2.

 

Are there any appraisal rights or dissenters’ rights?

 

Under the Florida Business Corporation Act, our shareholders are not entitled to dissenters’ or appraisal rights with respect to any of the proposals.

 

How does the Board recommend that I vote?

 

The Board recommends that you vote:

 

·

“FOR” the election of the director nominee named in this Proxy Statement to serve on the Board as a Class III director for a three-year term that will expire at our 2029 annual meeting of shareholders (Proposal 1);

 

 

·

“FOR” the ratification of the selection of Rosenberg Rich Baker Berman & Co. as our independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 2);

 

 

·

“FOR” the approval, on a non-binding, advisory basis, the compensation of the Company’s named executive officers (Proposal 3);

 

 

·

“FOR” the approval of the TOMI Environmental Solutions, Inc. 2026 Equity Incentive Plan, including the reservation of 3,500,000 shares of Common Stock for issuance thereunder (Proposal 4);

 

 

· 

“FOR” the approval of the Preferred Stock Charter Amendment (Proposal 5A); and

 

 

· 

“FOR” the approval of the Quorum Charter Amendment (Proposal 5B)

 

If I give a proxy, how will my shares be voted?

 

Proxy cards received by us before the Annual Meeting that are properly executed and dated will be voted at the Annual Meeting in accordance with the instructions indicated thereon. If the Annual Meeting is postponed or adjourned, your proxy will remain valid and may be voted at the postponed or adjourned meeting, and you will be able to revoke your proxy until it is voted at the postponed or adjourned meeting.

 

If you properly execute and date your proxy card but do not include voting instructions, your proxy card will be voted in accordance with the recommendation of the Board on all matters presented in this Proxy Statement. If you vote via the Internet using the website noted on your proxy card, you do not need to return your proxy card.

 

 
7

Table of Contents

 

What if other matters are voted on at the Annual Meeting?

 

With respect to any other matter that properly comes before the Annual Meeting, shares represented by valid proxies will be voted by the Proxy Holder in accordance with the Proxy Holder’s best judgment and in the manner the Proxy Holder believes to be in our best interests. For example, if you do not give instructions on your proxy card or by Internet, and a nominee for director listed on the proxy card withdraws before the Annual Meeting (which is not now anticipated), your shares will be voted by the Proxy Holder for any substitute nominee nominated by the Board. On the date this Proxy Statement was filed with the SEC, the Board did not know of any other matter to be brought before the Annual Meeting.

 

How will my shares be voted if I mark “WITHHOLD AUTHORITY” or “Abstain” on my proxy card?

 

We will count a properly executed proxy card marked “WITHHOLD AUTHORITY” and “ABSTAIN” as present for purposes of determining whether a quorum is present, but the shares represented by that proxy card will not be voted at the Annual Meeting with respect to Proposals 1, 2, 3, 4, 5A, and 5B.

 

What does it mean if I receive more than one proxy card?

 

If you hold your shares of Voting Stock in more than one account, you will receive a proxy card for each account. To ensure that all of your shares are voted, please vote using each proxy card you receive or, if you vote via the Internet, you will need to enter each of the voter control numbers, which may be found on each of your proxy cards. Remember, you may vote via the Internet using your control number found on your proxy card or by signing, dating and returning the proxy card, as applicable, in the postage-paid envelope provided.

 

How can I find out the results of the voting at the Annual Meeting?

 

Preliminary voting results will be announced at the Annual Meeting. Final voting results will be published in a Current Report on Form 8-K, which we will file with the SEC within four business days after the date of the Annual Meeting.

 

When are shareholder proposals due for the next annual meeting?

 

Under Rule 14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), any shareholder desiring to include a proposal in our proxy statement with respect to our 2027 annual meeting of shareholders should arrange for such proposal to be delivered to our corporate headquarters at TOMI Environmental Solutions, Inc., 8430 Spires Way, Frederick, Maryland 21701, Attention: Corporate Secretary, no later than [●], 2027, in order to be considered for inclusion therein. Matters pertaining to such proposals, and the eligibility of persons entitled to have such proposals included, are regulated by the Exchange Act and the rules of the SEC. Although the Board will consider shareholder proposals, we reserve the right to omit from our proxy statement, or to recommend votes against, shareholder proposals that we are not required to include under Rule 14a-8 under the Exchange Act.

 

Who is paying for this proxy solicitation?

 

We will bear the entire cost of solicitation of proxies, including preparation, assembly, printing, and mailing of this Proxy Statement, the proxy cards and any additional information furnished to shareholders. Copies of solicitation materials will be furnished to brokerage firms, banks, dealers and other similar organizations holding in their names shares of Voting Stock beneficially owned by others to forward to such beneficial owners. We may reimburse persons representing beneficial owners of Voting Stock for their costs of forwarding solicitation materials to such beneficial owners. In addition to the mailing of this Proxy Statement, the solicitation of proxies or votes may be supplemented by telephone, electronic communication, or personal solicitation by directors, officers or other employees of the Company. No additional compensation will be paid to our directors, officers or other employees for such services.

 

Whom should I contact with other questions?

 

If you have additional questions about this Proxy Statement or the Annual Meeting, please contact our investor relations department either by telephone at (800) 525-1698 or by email to info@tomimist.com.

 

 
8

Table of Contents

 

PROPOSAL 1: ELECTION OF CLASS III DIRECTORS

 

The Board consists of five directors and one vacancy divided into three classes, with each class holding office for a three-year term. Each director serves until his or her successor is duly elected and qualified, or until his or her earlier resignation or removal. One Class III director will be elected to the Board at the Annual Meeting and, upon such election, there will be five directors serving on the Board, as there is presently a vacancy on the Board in a seat reserved for a Class III director.

 

Upon the recommendation of the Nominating and Governance Committee of the Board, the Board has nominated Dr. Halden S. Shane for election at the Annual Meeting as a Class III director, to serve for a three-year term that will expire at our 2029 annual meeting of shareholders. Dr. Shane has consented to serve if elected. If Dr. Shane becomes unavailable to serve as a director, the Board may designate a substitute nominee. In that case, the Proxy Holder will vote for the substitute nominee designated by the Board. The Board has no reason to believe that Dr. Shane will be unable to serve. There are no agreements or understandings pursuant to which Dr. Shane, or any of our other directors, was selected to serve as a director.

 

All of our directors are expected to attend the virtual Annual Meeting.

 

INFORMATION ABOUT THE CLASS III DIRECTOR NOMINEE

 

The following section provides information regarding the Class III director nominee, including his age, the month and year in which each he first became a director, the class of our directors to which he currently serve or has been nominated, each committee of the Board on which he currently serves, professional experience during the past five years, any directorships with other public companies or registered investment companies currently or at any time during the past five years held by them, and a description of the particular experience, qualifications, attributes or skills that led the Board to conclude that they should serve as one of our directors.

 

Name

 

Age

 

Class

 

Serving Since

Halden S. Shane

 

82

 

Class III

 

October 2007

 

Dr. Halden S. Shane

 

Dr. Shane has been our Chief Executive Officer and Chairman of the Board, and has served as a member of the Board, since October 2007, when we commenced our current operations. From January 1992 until January 2009, Dr. Shane served as the President and Chief Executive Officer of Tiger Management International, a private management company that deals in business management of private and public companies. Dr. Shane was the founder and Chief Executive Officer of Integrated Healthcare Alliance, Inc. and founder and General Partner of Doctors Hospital West Covina, California. Prior thereto, Dr. Shane practiced Podiatric Surgery specializing in ankle arthroscopy. Dr. Shane received his Bachelor of Science degree from the University of Miami in 1969, his Bachelor of Medical Science degree from California College of Podiatric Medicine in 1971, and his Doctor of Podiatric Medicine Degree from the California College of Podiatric Medicine in 1973. He is Board Certified by the American Board of Podiatric Surgery, American Board of Orthopedics, and the American Board of Quality Assurance and Review. We believe that Dr. Shane’s extensive experience in the medical field and financial services industry qualifies him to serve on the Board.

 

Vote Required

 

The Class III director nominee receiving the highest number of votes “FOR” election at the Annual Meeting shall be elected to the Board. Abstentions and broker non-votes will have no effect in determining the results of the voting on the Class III director nominee at the Annual Meeting.

 

Proxies received in response to this solicitation will be voted “FOR” the election of Dr. Shane to the Board, unless otherwise specified in the proxy. The proxies cannot be voted for a greater number of persons than the number of director nominees named herein. If a Class III director nominee is unable or refuses to serve as a director, then the Proxy Holder will vote “FOR” the election of the substitute nominee or nominees designated by the Board, unless otherwise specified in the proxy.

 

Board Recommendation

 

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” THE ELECTION OF THE CLASS III DIRECTOR NOMINEE NAMED IN THIS PROXY STATEMENT.

 

 
9

Table of Contents

 

CONTINUING DIRECTORS

 

The following section provides information regarding each of our continuing directors, including his or her age, the month and year in which each he or she first became one of our directors, the class of our directors to which he or she has been elected, each committee of the Board on which he or she serves, his or her professional experience during the past five years, any directorships with other public companies or registered investment companies currently or at any time during the past five years held by him or her, and a description of the particular experience, qualifications, attributes or skills that led the Board to conclude that he or she should serve as one of our directors.

 

Name

 

Age

 

Class

 

Serving Since

Elissa J. Shane(1)

 

47

 

Class I

 

July 2021

Boh Soon Lim(1)(2)(3)(4)

 

70

 

Class I

 

January 2018

Francesco Fragasso(1)(2)(3)(4)(5)(7)

 

58

 

Class II

 

September 2025

Harold Paul(1)(2)(3)(6)

 

78

 

Class II

 

September 2025

___________________________________ 

(1)

The term of our Class I directors will expire at our 2027 annual meeting of shareholders and the term of our Class II director will expire at our 2028 annual meeting of shareholders.

 

 

(2)

Member of the Audit Committee.

 

 

(3)

Member of the Compensation Committee.

 

 

(4)

Member of the Nominating and Governance Committee.

 

 

(5)

Chair of the Audit Committee.

 

 

(6)

Chair of the Nominating and Governance Committee.

 

 

(7)

Chair of the Compensation Committee.

 

Elissa J. Shane

 

Ms. Shane has been our Chief Operating Officer since January 2018. On July 30, 2021, at the recommendation of the Nominating and Governance Committee, the Board appointed Ms. Elissa J. Shane to serve as a member of the Board. Previously, she served as our Chief Regulatory and Compliance Officer from September 2015 to December 2017 and as our Corporate Secretary in 2016. Ms. Shane received a B.A. in Psychology and Communications with a minor in Economics from the University of Southern California in 2001.   We believe that Ms. Shane’s experience, expertise and knowledge of our day-to-day business operations will contribute significantly to the Board’s oversight functions of the Company.

 

Dr. Lim Boh Soon

 

Dr. Lim has served as a member of the Board since January 2018 and has more than 28 years of experience in the banking and finance industry. For more than five years, he has been a fellow of the Singapore Institute of Directors and currently serves as an independent non-executive director of a company listed on the Singapore Exchange. Dr. Lim has held various directorships, including with V.S. Industry Berhad until January 2026, Kairos Asia Outreach until June 2025, QQ Fintech Pte. Ltd. until August 2024, and Jumbo Group Limited until January 2024, among others. In addition to his role with TOMI Environmental Solutions, Inc., Dr. Lim currently holds directorships with Arise Asset Management Pte. Ltd., OUE Limited, TPT Corporation (Cayman Islands), ASRI Asset Management Pte. Ltd., EpicQuant Pte. Ltd., Kaiyi Private Fund Management Co. Ltd., and Cap 1 Financial Pte. Ltd. Dr. Lim has also held senior management positions with several regional and multinational organizations, including UBS Capital Asia Pacific Limited, The NatSteel Group, Rothschild Ventures Asia Limited, and The Singapore Technologies Group. He was also a member of the Regional Investment Committee for UBS AG in Asia. Dr. Lim graduated with First-Class Honours in Mechanical Engineering from the University of Strathclyde in the United Kingdom, formerly the Royal College of Science and Technology, in 1981 and obtained his Doctor of Philosophy in Mechanical Engineering from the University of Strathclyde in 1985. We believe that Dr. Lim’s experience as a director of public companies and in the finance industry qualifies him to serve on the Board.

 

 
10

Table of Contents

 

Francesco Fragasso

 

Mr. Fragasso has served as a member of our board since September 2025, and serves as the Chairperson of the Audit Committee and Compensation Committee and a member of the Nominating and Governance Committee. Mr. Fragasso served as the Chief Financial Officer of Hamilton Thorne Ltd., a publicly traded company listed on the Toronto Stock Exchange (TSX: HTML), since August 2022 to January 2025. From 2018 to 2022, he served as Chief Financial Officer of Fluence Corporation Ltd., a global water infrastructure company listed on the Australian Securities Exchange. Mr. Fragasso served as Vice President and Chief Financial Officer at Desal tech, Inc. from 2015 to 2018, and served as Corporate CFO and Vice President of Operations at Novara Fuel Cells, Inc. from 2001 to 2014. He previously held senior finance and operations roles at MMN SpA. and Deloitte SpA in Italy.

 

Mr. Fragasso is a European Chartered Public Accountant and holds an MBA from Boston University and a Bachelor and Master of Science in Business and Economics from Università Bocconi in Milan, Italy. The Board believes that Mr. Fragasso’s substantial experience and expertise in financial and accounting matters, including public company financial reporting process, qualifies him to serve on the Board.

 

Harold Paul

 

Mr. Paul, has served as a member of our board since September 25, 2025, and previously served as a member of the Board of the Company from June 2009 until July 2021, and as the Company’s Corporate Secretary from March 2018 until July 2021. Mr. Paul currently serves as the Chairperson of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Paul has been engaged in the private practice of law for more than 50 years, primarily as a securities specialist, during which time he has served as outside legal counsel to public companies listed on national securities exchanges, such as the NYSE American, The Nasdaq Stock Market, and the markets operated by the OTC Markets Group Inc. Mr. Paul has also served as a director for six public companies in a variety of industries, including technology and financial services.

 

Mr. Paul holds a Bachelor of Arts from the State University of New York at Stony Brook and a Juris Doctor from Brooklyn Law School, and is admitted to practice law in New York and Connecticut. The Board believes that Mr. Paul’s extensive experience in corporate governance, legal compliance and management of public companies qualifies him to serve on the Board.

 

 
11

Table of Contents

 

CORPORATE GOVERNANCE

 

Under the Amended Bylaws of Tomi Environmental Solutions, Inc., as amended from time to time (the “Bylaws”), the number of directors of the Company shall be not less than three nor more than seven, as fixed from time to time by the shareholders or the Board. The Board has fixed the number of members at six directors. The Board currently consists of five directors and is divided into three classes, with each class holding office for a three-year term. One Class III director will be elected to the Board at the Annual Meeting and, upon such election, there will be five directors serving on the Board, as there is presently a vacancy on the Board in a seat reserved for a Class III director. Our Bylaws provide that our directors will hold office until their successors have been duly elected and qualified, or until their earlier resignation or removal. The Board is responsible for our business and affairs and considers various matters that require its approval.

 

Our Common Stock is currently quoted on the Nasdaq Capital Market (“Nasdaq”) under the symbol “TOMZ.” We are required to comply with the applicable Nasdaq listing standards as noted below.

 

Independence of the Board

 

As required by the listing requirements and rules of Nasdaq, a majority of the members of the Board must qualify as “independent,” as affirmatively determined by the Board. The Board annually reviews all relevant business relationships that any director or director nominee may have with us, our affiliates, and other companies. The Board also considers significant non-business relationships disclosed to us. As a result of its annual review and based upon information requested from and provided by each director and director nominee concerning his or her background, employment and affiliations, including family and other relationships, the Board has affirmatively determined in 2026 that each of Messrs. Fragasso, Paul, and Dr. Lim do not have any relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the applicable the rules of the SEC and the listing standards of Nasdaq and any other applicable laws or regulations.

 

In making these determinations, the Board considered the current and prior relationships that each non-employee director and director nominee, or any of his or her family members, has with us, our management and our independent auditors, and all other facts and circumstances deemed relevant in determining their independence, including any relationships described under the heading “Certain Relationships and Related Transactions-Transactions with Related Persons.”

 

In determining the independence of Mr. Paul, the Board considered that Mr. Paul provides advisory legal services to the Company pursuant to a legal services agreement with Harold Paul, LLC, a limited liability company of which Mr. Paul is the sole member. In exchange for Mr. Paul’s services, the Company paid Harold Paul, LLC approximately $93,750 during 2025.

 

Meetings of the Board

 

During the fiscal year ended December 31, 2025, the Board met 4 times and took action by unanimous written consent 3 times. Each incumbent director serving during the fiscal year ended December 31, 2025, attended at least 100% of all Board and applicable committee meetings during the period that he or she served as a director.

 

We make every effort to schedule our annual meeting of shareholders at a time and date to maximize attendance by directors, taking into account our directors’ schedules. All directors are strongly encouraged to make every effort to attend our annual meeting of shareholders, absent an unavoidable and irreconcilable conflict. All of our directors who were serving at the time of our 2025 annual meeting of shareholders attended such meeting.

 

Information Regarding Committees of the Board

 

The Board has three standing committees: the Audit Committee, the Compensation Committee and the Nominating and Governance Committee. Each such committee operates under a charter that has been approved by the Board. We intend to appoint persons to the Board and its committees as required from time to time to satisfy the corporate governance requirements of the Nasdaq listing rules. Below is a description of each committee.

 

 
12

Table of Contents

 

Audit Committee

 

Our Audit Committee was established in June 2009 and currently is comprised of Messrs. Fragasso and Paul and Dr. Lim, with Mr. Fragasso serving as chairperson of the Audit Committee.  At the conclusion of the Annual Meeting, the members of the Audit Committee are expected to be Messrs. Fragasso and Mr. Paul and Dr. Lim, and Mr. Fragasso is expected to continue serving as chairperson of the Audit Committee. The Audit Committee operates under a written charter, which can be found on the corporate governance section of our investor relations website at http://investor.tomimist.com/TOMZ. The purpose of the Audit Committee is to assist the Board in monitoring the integrity of our annual, quarterly and other financial statements, the independent auditor’s qualifications and independence, the performance of our independent auditors and our compliance with legal and regulatory requirements. The Audit Committee also reviews and approves all related-party transactions.

 

The Board has determined that each of the members of our audit committee satisfies the Nasdaq listing standards and the SEC independence requirements, and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. Further, the Board has determined that Mr. Fragasso qualifies as an audit committee financial expert within the meaning of SEC regulations and meets Nasdaq’s financial sophistication requirements. In making this determination, the Board has considered Mr. Fragasso’s extensive financial experience and business background.

 

The Audit Committee met 4 times during the fiscal year ended December 31, 2025.

 

Compensation Committee

 

The Compensation Committee was established in February 2011 and currently is comprised of Mr. Fragasso, Mr. Paul, and Dr. Lim, with Mr. Fragasso serving as chairperson of the Compensation Committee. At the conclusion of the Annual Meeting, the members of the Compensation Committee are expected to be Mr. Fragasso, Dr. Lim, and Mr. Paul, and Mr. Fragasso is expected to serve as chairperson of the Compensation Committee. The Compensation Committee operates under a written charter, which can be found on the corporate governance section of our investor relations website at http://investor.tomimist.com/TOMZ. The purpose of the Compensation Committee is to assist the Board in determining appropriate compensation levels for our executive officers; evaluating officer and director compensation plans, policies and programs; reviewing benefit plans for officers and employees; and producing the report required by applicable rules and regulations of the SEC and other applicable regulatory bodies for inclusion in our annual proxy statement. In addition, the Compensation Committee may exercise any other powers and carry out any other responsibilities delegated to it by the Board from time to time consistent with our Bylaws and applicable laws and regulations.

 

The Board has determined that each of the members of our Compensation Committee satisfies the Nasdaq listing standards and the SEC independence requirements, and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act.

 

The Compensation Committee met 2 times during the fiscal year ended December 31, 2025.

 

For additional information regarding the Compensation Committee’s consideration and determination of executive officer and director compensation, see the section entitled “Non-Employee Director Compensation” of this Proxy Statement.

 

 
13

Table of Contents

 

Nominating and Governance Committee

 

The Nominating and Governance Committee was established in January 2016 and currently consists of Mr. Fragasso, Mr. Paul and Dr. Lim, and Mr. Paul serves as chairperson of the Nominating and Governance Committee. At the conclusion of the Annual Meeting, the members of the Nominating and Governance Committee are expected to be comprised of Mr. Fragasso, Mr. Paul and Dr. Lim, and Mr. Paul is expected to continue serving as chairperson of the Nominating and Governance Committee. The Nominating and Governance Committee operates under a written charter, which can be found on the corporate governance section of our investor relations website at http://investor.tomimist.com/TOMZ. The purpose of the Nominating and Governance Committee is to identify individuals qualified to become members of the Board and to recommend such individuals to the Board as director nominees, as well as to develop and recommend to the Board corporate governance principles, to recommend Board committee membership and responsibilities, and to oversee the evaluation of the Board, its committees and management. In addition to other powers and responsibilities, the Nominating and Governance Committee will (i) identify individuals whom it believes are qualified to become Board members in accordance with applicable criteria, and recommend that the Board select such individuals as nominees to stand for election at each annual meeting of shareholders; (ii) review and evaluate all persons properly recommended by shareholders to be Board nominees; (iii) evaluate the qualifications and performance of incumbent directors and determine whether to recommend them for re-election to the Board; (iv) in the case of a Board vacancy, recommend to the Board in accordance with applicable criteria an individual to fill such vacancy either through election by the Board or through election by our shareholders; (v) review the independence of our directors; (vi) review reports and disclosures of insider and affiliated party transactions and make recommendations to the Board regarding such transactions; (vii) evaluate periodically the desirability of, and recommend to the Board, any changes in the size, composition, organization and operational structure of the Board; (viii) review annually membership and responsibilities of Board committees and recommend to the Board any changes that may be appropriate; and (ix) conduct an annual performance evaluation of the Nominating and Governance Committee.

 

The Board has determined that each of the members of our Nominating and Governance Committee satisfies the Nasdaq listing standards and the SEC independence requirements.

 

The Nominating and Governance Committee identifies potential director candidates through a variety of sources, including recommendations made by members of the Board and members of our executive management. When appropriate, the Nominating and Governance Committee may retain a search firm to identify director candidates.

 

The Nominating and Governance Committee charter provides that the committee will consider, among other things, the applicable requirements for directors under the Exchange Act, the listing standards of Nasdaq and applicable state law in evaluating potential director candidates. Additionally, the Nominating and Governance Committee may take into consideration such other factors and criteria as it deems appropriate in evaluating a candidate, including:

 

·

his or her knowledge, expertise, skills, integrity, diversity, judgment, business or other experience;

 

 

·

his or her reputation in the business community;

 

 

·

the interplay of the candidate’s experience with the experience of other Board members; and

 

 

·

the extent to which the candidate would be a desirable addition to the Board and any committees.

 

The Nominating and Governance Committee reviews and assesses at least annually the skills and characteristics of Board members, as well as the composition of the Board as a whole. The Nominating and Governance Committee’s assessment includes a review of our directors’ respective independence qualifications, skills and experience in the context of the needs of the Board. Additionally, the Nominating and Governance Committee considers diversity of the Board members’ skill and experience in areas that are relevant to our business and activities, including operations, finance, marketing and sales. The Board does not, however, have a formal policy regarding racial/ethnic, gender or other diversity of director candidates, but considers diversity as a factor in evaluating such candidates.

 

In assessing the composition of the Board, the Nominating and Governance Committee considers the Board’s current and anticipated needs, and seeks to maintain an appropriate balance of different business backgrounds, skills and expertise based on the nature and requirements of our business. In evaluating potential director candidates, the Nominating and Governance Committee considers all relevant information regarding such candidates, including the membership criteria stated above, and whether such candidates would meet the Nominating and Governance Committee’s objectives for the overall composition of the Board, as well as the candidates’ ability and willingness to devote adequate time to Board responsibilities. When appropriate, the Nominating and Governance Committee will recommend qualified candidates for nomination by the entire Board.

 

 
14

Table of Contents

 

The Nominating and Governance Committee met 2 times during the fiscal year ended December 31, 2025.

 

Code of Ethics

 

The Board adopted a Code of Ethics in 2008. It applies to, among other persons, Board members, officers including our Chief Executive Officer, contractors, consultants and advisors. Our Code of Ethics, which is available at http://investor.tomimist.com/TOMZ, sets forth written standards designed to deter wrongdoing and to promote:

 

·

honest and ethical conduct including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

 

 

·

full, fair, accurate, timely and understandable disclosure in reports and documents that we file with or submit to the SEC and in other public communications made by us;

 

 

·

compliance with applicable governmental laws, rules and regulations;

 

 

·

the prompt internal reporting of violations of the Code of Ethics to an appropriate person or persons identified in the Code of Ethics; and

 

 

·

accountability for adherence to the Code of Ethics.

 

 

·

We intend to post on our website any amendment to, or waiver from, the Code of Ethics as it applies to our principal executive officer, principal financial officer, principal accounting officer or controller, or other such persons performing similar functions. None of the information on the Company’s website is incorporated by reference in this Proxy Statement.

 

Insider Trading and Confidentiality Policy

 

We have adopted an insider trading and confidentiality policy that prohibits our directors, officers, employees, contractors and consultants from engaging in hedging or monetization transactions involving our securities.

 

Board Leadership Structure

 

The Board has not adopted a policy on whether the same individual should serve as both the Chief Executive Officer and Chairman of the Board or, if the roles are separate, whether the Chairman should be selected from the non-employee directors or should be an employee. The Board believes that it should maintain the flexibility to make such determinations in the manner that it believes best provides appropriate leadership for us at the relevant time. The Board believes that its current leadership structure, with Dr. Shane serving as both Chief Executive Officer and Chairman of the Board, is appropriate for us at this time because the combined role of the Chief Executive Officer and Chairman provides a clear chain of command to execute our strategic initiatives and business plans and allows such individual to serve as a bridge between management and the Board, which facilitates the regular flow of information.

 

Board Role in Risk Oversight

 

The Company’s risk assessment and management function is led by the Company’s senior management, which is responsible for day-to-day management of the Company’s risk profile, with oversight from our Board and its committees. The Board and its committees regularly liaise with management to assess and manage our major risk exposures, the potential impact of such risks on our business and the steps we should take to mitigate or manage such risks. The Board’s risk oversight process complements and supplements management’s risk assessment and mitigation processes, which include reviews of strategic and operational planning, executive development and evaluation, regulatory and legal compliance, and financial reporting and internal controls. The risk oversight process also includes receiving reports from committees of the Board and members of senior management to enable the Board to understand our risk identification, management and mitigation strategies with respect to areas of potential material risk.

 

 
15

Table of Contents

 

Central to our Board’s oversight function is our Audit Committee. In accordance with our Audit Committee Charter, our Audit Committee is responsible for the oversight of the financial reporting process and internal controls. In this capacity, our Audit Committee is responsible for reviewing and evaluating guidelines and policies governing the process by which senior management of the Company and the relevant departments of the Company, including the internal audit department, assess and manage the Company’s exposure to risk, as well as the Company’s major financial risk exposures and the steps management has taken to monitor and control such exposures. The Audit Committee’s risk management process involves direct communication with our independent registered public accounting firm and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The Nominating and Governance Committee manages risks associated with the independence of the Board, corporate disclosure practices and potential conflicts of interest. While each of our committees is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed about such risks, and matters involving significant risk are considered by the Board as a whole.

 

The Audit Committee is responsible for periodically reviewing our policies with respect to risk assessment and risk management. The Board has adopted, based on a recommendation from the Audit Committee, a written policy for how the Company’s internal audit department will treat aged accounts receivables.

 

Shareholder Communications with the Board

 

Shareholders wishing to communicate with the Board or with an individual Board member concerning the Company may do so by writing to the Board or to the particular Board member, and mailing the correspondence to TOMI Environmental Solutions, Inc., 8430 Spires Way, Frederick, Maryland 21701, Attention: Corporate Secretary. The envelope should indicate that it contains a shareholder communication.

 

All correspondence received is opened and screened for security purposes. Our Corporate Secretary reviews such correspondence and provides the Board at each of its meetings with a summary of all such correspondence and a copy of any correspondence that, in the opinion of the Corporate Secretary, deals with the functions of the Board or the standing committees of the Board or that otherwise requires their attention. The Corporate Secretary will not forward the communication if it is primarily commercial in nature or if it relates to an improper or irrelevant topic. Correspondence relating to accounting, internal controls or auditing matters will be handled in accordance with procedures established by the Audit Committee with respect to such matters.

 

Policies and Practices Related to the Grant of Certain Equity Awards Close in Time to the Release of Material Nonpublic Information

 

The Company does not currently grant new awards of stock options, stock appreciation rights, or similar option-like instruments. Accordingly, the Company has no specific policy or practice on the timing of awards of such options in relation to the disclosure of material nonpublic information by the Company. In the event the Company determines to grant new awards of such options, the Board and the Compensation Committee will evaluate the appropriate steps to take in relation to the foregoing.

 

 
16

Table of Contents

 

DELINQUENT SECTION 16(a) REPORTS

 

To the best of our knowledge, all reports that were required to be filed during the fiscal year ended December 31, 2025, by our executive officers, directors and beneficial owners of more than 10% of our Common Stock under Section 16 of the Exchange Act were filed on a timely basis, except that a Form 3 reporting the initial beneficial ownership of Harold Paul following his appointment to our Board of Directors on September 25, 2025, was filed late on October 7, 2025, and a Form 3 reporting the initial beneficial ownership of Francesco Fragasso following his appointment to our Board of Directors on September 11, 2025, was filed late on November 3, 2025.

 

REPORT OF THE AUDIT COMMITTEE

 

The primary responsibility of the Audit Committee is to assist the Board in discharging its oversight responsibilities with respect to financial matters and compliance with laws and regulations. The primary methods used by the Audit Committee to fulfill its responsibility with respect to financial matters are:

 

·

to appoint, evaluate, and, as the Audit Committee may deem appropriate, terminate and replace our independent registered public accountants;

 

 

·

to monitor the independence of our independent registered public accountants;

 

 

·

to determine the compensation of our independent registered public accountants;

 

 

·

to pre-approve any audit services, and any non-audit services permitted under applicable law, to be performed by our independent registered public accountants;

 

 

·

to review our risk exposures, the adequacy of related controls and policies with respect to risk assessment and risk management;

 

 

·

to monitor the integrity of our financial reporting processes and systems of control regarding our finance, accounting, legal compliance and information systems; and

 

 

·

to facilitate and maintain an open avenue of communication among the Board, our management and our independent registered public accountants.

 

In discharging its responsibilities relating to internal controls, accounting and financial reporting policies and auditing practices, the Audit Committee discussed with our independent registered public accountants, Rosenberg Rich Baker Berman & Co., the overall scope and process for its audit. The Audit Committee has met with Rosenberg Rich Baker Berman & Co., with and without management present, to discuss the results of its examinations and the overall quality of our financial reporting.

 

The Audit Committee has discussed with Rosenberg Rich Baker Berman & Co. its judgments about the quality, in addition to the acceptability, of our accounting principles as applied in our financial reporting, as required by applicable rules adopted by the Public Company Accounting Oversight Board (“PCAOB”).

 

The Audit Committee also has received a letter from Rosenberg Rich Baker Berman & Co. that is required by applicable requirements of the PCAOB regarding the independent accountant’s communications with the audit committee concerning independence, and has discussed with Rosenberg Rich Baker Berman & Co. their independence.

 

The Audit Committee has met and held discussions with management. The Audit Committee has reviewed and discussed with management our audited consolidated financial statements as of and for the years ended December 31, 2025 and 2024.

 

Based on the reviews and discussions referred to above, the Audit Committee recommended to the Board that the audited financial statements referred to above be included in our Annual Report on Form 10-K for the year ended December 31, 2025.

 

Respectfully submitted,

 

Francesco Fragasso, Committee Chairperson Lim Boh Soon

Harold Paul

 

 
17

Table of Contents

 

NON-EMPLOYEE DIRECTOR COMPENSATION

 

Each of our non-employee directors receives cash fees and stock as compensation for their service on the Board and the committees of the Board of which they are a member, in each case under individual director agreements that are described in the footnotes to the table below. The table below sets forth the compensation earned by each non-employee director during the fiscal year ended December 31, 2025. We qualify as a “smaller reporting company” under the rules promulgated by the Securities and Exchange Commission, and we have elected to comply with the Director Compensation disclosure requirements applicable to smaller reporting companies.

 

Name

 

Fees Earned or

Paid in Cash($)

 

 

Stock Awards(1)($)

 

 

All Other Compensation($)

 

 

Total($)

 

Walter Johnsen(1)

 

 

32,000

 

 

 

17,000

 

 

 

―

 

 

 

49,000

 

Kelly J. Anderson(2)

 

 

40,950

 

 

 

17,000

 

 

 

―

 

 

 

57,950

 

Lim Boh Soon(3)

 

 

41,000

 

 

 

17,000

 

 

 

―

 

 

 

58,000

 

Francesco Fragasso(4)

 

 

5,000

 

 

 

8,000

 

 

 

―

 

 

 

13,000

 

Harold W. Paul(5)

 

 

5,000

 

 

 

8,000

 

 

 

―

 

 

 

13,000

 

________________________________ 

(1)

Mr. Johnsen was elected to the Board on January 29, 2016. His director agreement provided for an annual fee in the amount of $48,000 paid on a quarterly basis and an annual grant of shares of common stock. In May 2025, we issued Mr. Johnsen 20,000 shares of common stock that were valued at $17,000. On September 11, 2025, Mr. Johnsen notified the Company of his resignation as a director of the Board, effective September 11, 2025. Cash fees of $32,000 reflect fees paid for two full quarters and two full months through August 31, 2025, the last fully completed month prior to his resignation on September 11, 2025.

 

 

(2)

Ms. Anderson was elected to the Board on January 29, 2016 and served as the chairperson of our Audit Committee. Her director agreement provided for an annual fee of $54,600 paid on a quarterly basis and an annual grant of shares of common stock. In May 2025, we issued Ms. Anderson 20,000 shares of common stock that were valued at $17,000. On September 26, 2025, Ms. Anderson notified the Company that she resigned as a director of the Company effective September 30, 2025. Cash fees of $40,950 reflect three quarters of her annual fee prorated through September 30, 2025.

 

 

(3)

Dr. Lim has served on the Board since January 29, 2018. Dr. Lim was reelected as a Class I director to the Board at the Company’s 2024 annual meeting of stockholders to serve a three-year term expiring at the 2027 Annual Meeting. His director agreement provides for an annual fee in the amount of $48,000 paid on a quarterly basis and an annual grant of shares of common stock. In May 2025, we issued Dr. Lim 20,000 shares of common stock that were valued at $17,000. During the fourth quarter of 2025, director agreements were modified to reduce the cash fees to $5,000 per quarter and increase the annual equity grant to 40,000 restricted stock units per year. Cash fees of $41,000 reflect $36,000 paid at the prior rate for the first three quarters of 2025 and $5,000 paid at the revised rate for the fourth quarter of 2025.

 

 

(4)

Mr. Fragasso was appointed to the Board on September 11, 2025. Mr. Fragasso serves on the Audit Committee, Compensation Committee and Nominating and Governance Committee. His director agreement provides for a cash fee of $5,000 per quarter and an annual grant of shares of common stock. During the fourth quarter of 2025, we issued Mr. Fragasso 10,000 shares of common stock that were valued at $8,000. Mr. Fragasso was subsequently elected by shareholders as a Class II Director at the Company’s 2025 annual meeting of stockholders, to serve a three-year term expiring at the 2028 Annual Meeting.

 

 

(5)

Mr. Paul was appointed to the Board on September 25, 2025. Mr. Paul previously served as a member of the Board from 2009 to 2021, including as Corporate Secretary from 2013 to 2021. Mr. Paul serves on the Audit Committee, Compensation Committee and as Chairman of the Nominating and Corporate Governance Committee. His director agreement provides for a cash fee of $5,000 per quarter and an annual grant of shares of common stock. During the fourth quarter of 2025, we issued Mr. Paul 10,000 shares of common stock that were valued at $8,000. Mr. Paul was subsequently elected by shareholders as a Class II Director at the Company’s annual meeting in November 2025, to serve a three-year term expiring at the 2028 Annual Meeting.

 

 
18

Table of Contents

 

INFORMATION REGARDING OUR EXECUTIVE OFFICERS

 

The following table identifies our current executive officers, their respective offices and positions and their respective dates of appointment:

 

Name

Age

Positions Held

Date of Appointment

Halden S. Shane

82

Chief Executive Officer and Chairman of the Board

October 15, 2007

Niroshan Srirathan (1)(2)(3)(4)

39

Chief Financial Officer

October 11, 2026

Elissa J. Shane

47

Chief Operating Officer

January 1, 2018

___________________________

(1)

On October 11, 2026, the Board appointed Niroshan Srirathan, former Interim Chief Financial Officer, as Chief Financial Officer. Mr. Srirathan has served as the Company’s Interim Chief Financial Officer since May 16, 2026.

 

Arrangements Involving Directors or Executive Officers

 

There is no arrangement or understanding between any of our directors or executive officers and any other person pursuant to which any director or officer was or is to be selected as a director or officer, and there is no arrangement, plan, or understanding as to whether non-management shareholders will exercise their voting rights to continue to elect the current Board. There are also no arrangements, agreements, or understandings to our knowledge between non-management shareholders that may directly or indirectly participate in or influence the management of our affairs.

 

Family Relationships

 

There are no family relationships between or among any of the current directors, executive officers or persons nominated or charged to become directors or executive officers, except that Elissa J. Shane, our Chief Operating Officer and a director, is the daughter of Dr. Halden S. Shane, our Chief Executive Officer and Chairman of the Board.

 

Business Experience

 

The business experience of our directors, including executive officers serving as directors, is provided under “Continuing Directors” in Proposal 1 above. The business experience of executive officers who are not also directors is described below.

 

Niroshan Srirathan, Chief Financial Officer

 

Mr. Srirathan has served as the Company’s Chief Financial Officer since October 11, 2026, the Company’s Interim Chief Financial Officer since May 16, 2026, and as the Company’s Controller since May 4, 2026. Prior to this, from April 2024 to January 2025, Mr. Srirathan served as Senior Finance Manager (Regional Comptroller) for Vistry Group plc, a UK public company. From May 2020 to February 2024, he served as Finance Transformation Lead (Group Comptroller Functions) for Berkeley Group Holdings plc, a UK public company. Earlier in his career, Mr. Srirathan held finance and accounting positions with Lendlease Corporation Limited and began his career in public accounting with Moore Stephens LLP, qualifying as a Chartered Accountant in 2012. Mr. Srirathan holds a BSc (Hons) in Economics from University College London and is an Associate Chartered Accountant (ACA) of the Institute of Chartered Accountants in England and Wales (ICAEW). He is currently pursuing qualification as a U.S. Certified Public Accountant (CPA) in Maryland and has completed a foreign education evaluation through NASBA International Evaluation Services (NIES).

 

 
19

Table of Contents

 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

The following table sets forth certain information with respect to the beneficial ownership of our Voting Stock as of November 2, 2026, for:

 

·

each person (or group of affiliated persons) known by us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock or Series A Preferred Stock.

 

 

·

each of our directors and nominees for election to the Board;

 

 

·

each of our executive officers named in the Summary Compensation Table; and

 

 

·

all of our directors and executive officers as a group.

 

We have determined beneficial ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished to us, that the persons and entities named in the following table have sole voting and investment power with respect to all shares of Voting Stock that they beneficially own, subject to applicable community property laws.

 

Applicable percentage ownership is based on 10,022,232 shares of Common Stock and 21,250 shares of Series A Preferred Stock outstanding on November 2, 2026. In computing the number of shares of Voting Stock beneficially owned by a person and the percentage ownership of that person, we deemed to be outstanding all shares of Voting Stock subject to options, warrants or other convertible securities held by that person or entity that are currently exercisable or releasable or that will become exercisable or releasable within 60 days of November 2, 2026. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. Except as otherwise noted, the address of each person or entity in the following table is c/o TOMI Environmental Solutions, Inc., 8430 Spires Way, Frederick, Maryland 21701.

 

 

 

Shares Beneficially Owned

 

 

% of Total

 

 

 

Common Stock

 

 

Series A Preferred Stock

 

 

Voting

 

Name of Beneficial Owner(1)(2)

 

Shares

 

 

% of Class

 

 

Shares

 

 

% of Class

 

 

Power(3)

 

5% Shareholders:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Lau Sok Huy(4)

 

 

723,380

 

 

 

7.2%

 

 

―

 

 

 

―

 

 

 

7.2%

Named Executive Officers and Directors

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Halden S. Shane(3)(5)

 

 

1,401,472

 

 

 

13.4%

 

 

21,250

 

 

 

100.0%

 

 

13.6%

Elissa J. Shane(6)

 

 

143,806

 

 

 

1.4%

 

 

―

 

 

 

―

 

 

 

1.4%

Niroshan Srirathan

 

 

―

 

 

*

 

 

 

―

 

 

 

―

 

 

*

 

Francesco Fragasso(7)

 

 

10,000

 

 

*

 

 

 

―

 

 

 

―

 

 

*

 

Harold Paul(8)

 

 

30,434

 

 

*

 

 

 

―

 

 

 

―

 

 

*

 

Lim Boh Soon(9)

 

 

69,508

 

 

*

 

 

 

―

 

 

 

―

 

 

*

 

Executive Officers and Directors as a Group(10)

 

 

1,655,220

 

 

 

15.7%

 

 

21,250

 

 

 

100.0

%

 

 

15.9%

___________________________________ 

* Denotes ownership of less than 1%.

 

 

(1)

Unless otherwise noted, the business address for each of the following entities or individuals is 8430 Spires Way, Frederick, Maryland 21701.

 

 

(2)

Reflects the 1-for-3 reverse stock split of our Common Stock and Series A Preferred Stock effected on July 20, 2026.

 

 

(3)

Percentage of total voting power represents voting power with respect to all shares of our Common Stock and Series A Preferred Stock, as a single class. The holders of Common Stock and Series A Preferred Stock are each entitled to one vote per share on each matter submitted to shareholders at the Annual Meeting.

 

 

(4)

Based on a Schedule 13D filed with the SEC by Lau Sok Huy on August 1, 2017, as amended. The address of the shareholder is 96 Robinson Road #11-04, SIF Building, Singapore 068899.

 

 
20

Table of Contents

 

(5)

Consists of: (i) 846,056 shares of Common Stock held of record by Dr. Shane; (ii) 62,500 shares of Common Stock held of record by the Shane Family Trust; (iii) 41,667 shares of Common Stock held of record by Belinha Shane; and (iv) 451,250 shares of Common Stock issuable upon the exercise of warrants and options to purchase Common Stock held by Dr. Shane that are exercisable or will become exercisable within 60 days of November 2, 2026. Dr. Shane is a co-trustee of the Shane Family Trust and may be deemed to share voting and investment power over the securities held by the trust. Belinha Shane is Dr. Shane’s wife. Dr. Shane disclaims ownership of such shares held by his wife, except to the extent of his pecuniary interest.

 

 

(6)

Consists of: (i) 89,221 shares of Common Stock held of record by Ms. Shane; and (ii) 54,584 shares of Common Stock issuable upon the exercise of warrants and options to purchase Common Stock held by Ms. Shane that are exercisable or will become exercisable within 60 days of November 2, 2026.

 

 

(7)

Consists of: 10,000 shares of Common Stock held of record by Mr. Fragasso.

 

 

(8)

Consists of: 30,434 shares of Common Stock held of record by Mr. Paul.

 

 

(9)

Consists of: 69,508 shares of Common Stock held of record by Dr. Lim.

 

 

(10)

Consists of: (i) 1,149,386 shares of Common Stock; (ii) 329,167 shares of Common Stock issuable upon the exercise of warrants to purchase Common Stock; and (iii) 176,667 shares of Common Stock issuable upon exercise of stock options that are exercisable or will become exercisable within 60 days of November 2, 2026.

 

Change in Control

 

We are unaware of any contract or other arrangement the operation of which may at a subsequent date result in a change of control of our Company.

 

Legal Proceedings

 

To our knowledge, none of our directors, officers or affiliates, or any 5% or greater shareholder, or any associate or any such directors, officers or affiliates, is a party that is adverse to us in any material legal proceeding.

 

EXECUTIVE COMPENSATION

 

Summary Compensation Table

 

The following table sets forth the total compensation earned by our named executive officers for the years ended December 31, 2025 and 2024, respectively, in accordance with SEC rules under Item 402(c) of Regulation S-K. Amounts shown represent compensation earned during each fiscal year regardless of whether paid in cash during the year. For the year ended December 31, 2025, a portion of the salary earned by Dr. Halden S. Shane and Ms. Elissa J. Shane was not paid in cash and remains accrued as of December 31, 2025. See footnote (2) below:

 

Name and Principal Position

 

Year

 

Salary ($)

 

 

Bonus ($)

 

 

Stock Awards ($)(1)

 

 

Option / Warrant Awards ($)(1)

 

 

All Other Compensation ($)

 

 

Total ($)

 

Halden S. Shane(2)

 

2025

 

 

605,000

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

9,000

 

 

 

614,000

 

Chief Executive Officer and Chairman of the Board

 

2024

 

 

499,125

 

 

 

―

 

 

 

―

 

 

 

64,136

 

 

 

9,000

 

 

 

572,261

 

Elissa J. Shane(2)

 

2025

 

 

326,700

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

12,000

 

 

 

338,700

 

Chief Operating Officer

 

2024

 

 

269,528

 

 

 

―

 

 

 

―

 

 

 

32,068

 

 

 

12,000

 

 

 

313,596

 

David Vanston(3)

 

2025

 

 

123,846

 

 

 

―

 

 

 

―

 

 

 

99,830

 

 

 

3,250

 

 

 

226,926

 

Chief Financial Officer

 

2024

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

Nick Jennings(4)

 

2025

 

 

75,000

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

75,000

 

Interim Chief Financial Officer

 

2024

 

 

104,552

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

104,552

 

Joe Rzepka(5)

 

2025

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

 

 

―

 

Chief Financial Officer

 

2024

 

 

84,020

 

 

 

―

 

 

 

―

 

 

 

48,102

 

 

 

―

 

 

 

132,122

 

 

 
21

Table of Contents

___________________________________ 

(1)

The amounts shown in this column represent the aggregate grant date fair value of stock, option and/or warrant award, as applicable, granted during the year computed in accordance with FASB ASC Topic 718. See Note 2 of the notes to our audited consolidated financial statements contained in the Annual Report on Form 10-K for the year ended December 31, 2025, for a discussion of valuation assumptions made in determining the grant date fair value of the awards.

 

 

(2)

For the year ended December 31, 2025, a portion of the salary amounts shown for Dr. Halden S. Shane, Chairman and Chief Executive Officer, and Ms. Elissa J. Shane, Chief Operating Officer, was earned but not paid in cash during the fiscal year as a cash conservation measure adopted by the Company in light of its liquidity position. The earned but unpaid amounts totaling approximately $476,000, have been fully accrued as compensation payable in accordance with ASC 710 and are included within the payroll and related costs balance in accrued expenses and other current liabilities on the Company's Consolidated Balance Sheet as of December 31, 2025. See Note 13 to the consolidated financial statements for further information. The Company intends to satisfy these obligations as operating cash flow permits. The salary amounts shown in the table above represent the full contractual amounts earned during fiscal 2025 and are reported in accordance with Item 402(c) of Regulation S-K.

 

 

(3)

On October 6, 2025, the Company granted Mr. Vanston 100,000 restricted stock units under the 2016 Equity Incentive Plan. The grant date fair value of $99,830 was calculated based on the closing stock price of $0.9983 per share on the grant date, computed in accordance with FASB ASC Topic 718. Please refer to Item 11 Employment Agreements for additional details regarding Mr. Vanston’s compensation arrangements, including the vesting schedule.

 

 

(4)

Mr. Jennings served as our Chief Financial Officer from September 2015 until May 2024 and as Interim Chief Financial Officer from December 2024 through May 2025. During the year ended December 31, 2024, he was entitled to an annual salary of $211,750, of which he received $104,552 through May 2024. During the year ended December 31, 2025, he received a monthly fee of $15,000 for five months, totaling $75,000.

 

 

(5)

Mr. Rzepka served as our Chief Financial Officer from May 2024 through December 2024. During the year ended December 31, 2024, we issued an option to purchase 75,000 shares of common stock to Mr. Rzepka at an exercise price of $0.75 per share pursuant to an employment agreement. The option was valued at $48,102 and has a contractual term of 10 years. We utilized the Black-Scholes model to fair value the option received by our former Chief Financial Officer with the following assumptions: volatility, 125%; expected dividend yield, 0%; risk free interest rate, 4.35%; and an expected life of 10 years. The grant date fair value of each share of common stock underlying the option was $0.64. Please refer to Item 11 Employment Agreements for additional details of Mr. Rzepka’s annual compensation.

 

Narrative Disclosure to Summary Compensation Table

 

Except as described below, we currently have no employment agreements with any of our executive officers, nor any compensatory plans or arrangements providing for compensation as a result of the resignation, retirement or any other termination of any of our executive officers, from a change-in-control, or from a change in any executive officer’s responsibilities following a change-in-control.

 

Employment Agreements

 

We have entered into employment agreements with each of the named executive officers and generally include the named executive officer’s initial base salary and an indication of equity compensation opportunities.

 

Dr. Halden S. Shane

 

On September 22, 2020, we entered into a three-year employment agreement with Dr. Shane, effective October 1, 2020. The agreement provides for an initial base annual salary of $500,000. Dr. Shane's annual base salary has been subsequently increased to $605,000 pursuant to annual reviews by the Compensation Committee. The agreement also provides for a signing bonus of 375,000 warrants. Dr. Shane is also entitled to a cash performance bonus and an annual issuance of an option to purchase 31,250 shares of common stock from the 2016 Plan at the discretion of the Board. The agreement also provides that we will reimburse Dr. Shane for the expenses associated with the use of an automobile up to $750 per month. The initial term of his employment agreement is three years, which may be automatically extended for successive one-year terms, unless either party provides the other with 120 days' prior written notice of its intent to terminate the agreement.

 

 
22

Table of Contents

 

In June 2024, for the purpose of implementing cost-saving measures to reduce cash requirements and achieve profitability objectives, Dr. Shane's annual salary was reduced by 30% from $605,000 to $423,500 from June 1, 2024 through December 31, 2024. Effective January 1, 2025, Dr. Shane's annual base salary was restored to $605,000.

 

In the event Dr. Shane is terminated as Chief Executive Officer as a result of a change in control, Dr. Shane will be entitled to a lump sum payment of two years' salary at the time of such termination.

 

Elissa J. Shane

 

On October 1, 2020, we entered into an employment agreement with Elissa J. Shane, effective October 1, 2020. Pursuant to her employment agreement, Ms. Shane received an initial annual base salary of $270,000, subject to annual review and discretionary increase by the Compensation Committee of the Board. Ms. Shane's annual base salary has been subsequently increased to $326,700 pursuant to annual reviews by the Compensation Committee. Ms. Shane is eligible to receive an annual cash bonus and other annual incentive compensation. Ms. Shane is also entitled to the sum of $1,000 per month as a vehicle allowance. The initial term of her employment agreement is three years, which may be automatically extended for successive one-year terms, unless either party provides the other with 120 days' prior written notice of its intent to terminate the agreement.

 

In June 2024, for the purpose of implementing cost-saving measures to reduce cash requirements and achieve profitability objectives, Ms. Shane's annual salary was reduced by 30% from $326,700 to $228,690 from June 1, 2024 through December 31, 2024. Effective January 1, 2025, Ms. Shane's annual base salary was restored to $326,700.

 

In the event Ms. Shane is terminated as Chief Operating Officer as a result of a change in control, Ms. Shane will be entitled to a lump sum payment of one and a half years’ salary at the time of such termination.

 

OUTSTANDING EQUITY AWARDS AT 2025 FISCAL YEAR-END

 

The following table sets forth certain information with respect to outstanding warrants and options to purchase Common Stock previously awarded to our named executive officers as of December 31, 2025.

 

Name

Number of Securities Underlying Unexercised Warrants / Options Exercisable(1) (#)

Number of Securities Underlying Unexercised Warrants / Options Unexercisable (#)

Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Warrants (#)

Exercise Price($)(1)

Expiration Date

Halden S. Shane

12,500(2)

―

―

4.00

4/24/2030

375,000(3)

―

―

6.95

10/1/2030

172,500(4)

―

―

1.12

1/18/2032

437,500(5)

―

―

0.96

12/22/2032

31,250(6)

―

―

0.64

11/19/2032

125,000(7)

―

―

0.80

1/26/2034

100,000(8)

―

―

0.85

1/26/2033

100,000(9)

―

―

0.75

5/15/2034

Elissa J. Shane

6,250(10)

―

―

4.00

4/24/2030

 

57,500(11)

―

―

1.12

1/18/2032

 

50,000(12)

―

―

0.85

1/26/2033

 

50,000(13)

―

―

0.75

5/15/2034

David Vanston

66,666(14)

―

―

―

―

Nick Jennings

6,250(15)

―

―

4.00

4/24/2030

 

40,000(16)

―

―

1.12

1/18/2032

 

25,000(17)

―

―

0.85

1/26/2033

Joe Rzepka

4,500(18)

―

―

1.93

12/14/2026

 

7,042(19)

―

―

0.71

1/20/2028

 

75,000(20)

―

―

0.75

5/15/2034

 

 
23

Table of Contents

________________________________  

(1)

Reflects the 1-for-8 reverse stock split of our Common Stock and Series A Preferred Stock effected on September 10, 2020 and does not reflect the 1-for-3 reverse stock split of our Common Stock and Series A Preferred Stock effected on July 20, 2026.

 

 

(2)

Warrants vested on April 24, 2020, and have a term of ten years.

 

 

(3)

Warrants vested on October 01, 2020, and have a term of ten years.

 

 

(4)

Options vested on January 18, 2022, and have a term of ten years.

 

 

(5)

Warrants vested on December 22, 2017, and were modified to expire on December 22, 2032.

 

 

(6)

Warrants vested on November 19, 2018, and were modified to expire on November 19, 2032.

 

 

(7)

Warrants vested on January 26, 2019, and where modified to expire on January 26, 2034.

 

 

(8)

Options vested on January 26, 2023, and have a term of ten years.

 

 

(9)

Options vested on May 15, 2024, and have a term of ten years.

 

 

(10)

Warrants vested on April 24, 2020, and have a term of ten years.

 

 

(11)

Options vested on January 18, 2022, and have a term of ten years.

 

 

(12)

Options vested on January 26, 2023, and have a term of ten years.

 

 

(13)

Options vested on May 15, 2024, and have a term of ten years.

 

 

(14)

Includes 100,000 restricted stock units granted to the Company’s Chief Financial Officer, of which 66,666 remain unvested as of December 31, 2025. Restricted stock units have no exercise price or expiration date.

 

 

(15)

Warrants vested on April 24, 2020 and have a term of ten years.

 

 

(16)

Options vested on January 18, 2022 and have a term of ten years.

 

 

(17)

Options vested on January 26, 2023 and have a term of ten years.

 

 

(18)

Options vested on December 14, 2021 and have a term of five years.

 

 

(19)

Options vested on January 20, 2023 and have a term of five years.

 

 

(20)

Options vested on May 16, 2024 and have a term of ten years.

 

 
24

Table of Contents

 

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

Company Policies and Procedures

 

Although the Board has not adopted a written policy or procedure for the review, approval and ratification of related person transactions, the charter of the Audit Committee provides that the Audit Committee is responsible for reviewing and approving, on an ongoing basis, any proposed transaction with any related person for which disclosure and/or approval is required under applicable law, including pursuant to rules promulgated by the SEC. Currently, this review and approval requirement applies to any transaction to which we will be a party, in which the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any of the following persons will have a direct or indirect material interest: (a) any of our directors or executive officers; (b) any director nominee; (c) any security holder who is known to us to own, of record or beneficially, five percent or greater of any class of our voting securities; or (d) any member of the immediate family (as defined in Item 404 of Regulation S-K) of any of the persons described in the foregoing clauses (a)-(c).

 

In the event that management becomes aware of any related party transaction, management will present information regarding such transaction to the Audit Committee for review and approval. In addition, the Audit Committee periodically reviews and considers with management the disclosure requirements relating to transactions with related persons and the potential existence of any such transaction.

 

Certain Relationships

 

Elissa J. Shane is our Chief Operating Officer and a director. She is the daughter of Dr. Halden S. Shane, our Chief Executive Officer and Chairman of the Board.

 

Transactions with Related Persons

 

None.

 

EQUITY COMPENSATION PLAN INFORMATION

 

The following table provides information as of December 31, 2025 with respect to compensation plans under which our equity securities are authorized for issuance.

 

Plan Category

 

Number of securities to be issued upon exercise of outstanding options, warrants and rights(1)

 

 

Weighted-average exercise price of outstanding options, warrants and rights(1)

 

 

Number of securities remaining available for future issuance under equity compensation plans(1)

 

Equity compensation plans approved by security holders

 

 

837,542(2)

 

 

0.99(5)

 

 

592,708(4)

Equity compensation plans not approved by security holders

 

 

997,500(3)

 

 

3.27

 

 

 

―

 

Total

 

 

1,835,042

 

 

 

2.18

 

 

 

―

 

__________________________________ 

(1)

Reflects the 1-for-8 reverse stock split of our Common Stock and Series A Preferred Stock effected on September 10, 2020, and does not reflect the 1-for-3 reverse stock split of our Common Stock and Series A Preferred Stock effected on July 20, 2026.

 

 

(2)

Prior to August 25, 2015, we granted awards under the 2008 Plan.

 

 

(3)

Represents shares of common stock issuable upon the exercise of warrants issued to executive officers, employees and consultants in exchange for services rendered.

 

 

(4)

On July 7, 2017, the 2016 Plan received shareholder approval, which permits the grant up to 625,000 shares of common stock. On December 30, 2020, we received shareholder approval to amend and restate the 2016 Plan to increase the maximum number of shares of common stock authorized from issuance by 1,375,000, from 625,000 shares to 2,000,000.

 

 

(5)

Includes 100,000 restricted stock units granted to the Company’s Chief Financial Officer under the 2016 Plan, of which 66,666 remain unvested as of December 31, 2025. Restricted stock units have no exercise price and are excluded from the weighted average exercise price calculation.

 

 
25

Table of Contents

 

PAY VERSUS PERFORMANCE

 

In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and Item 402(v) of Regulation S-K, we provide the following disclosure regarding executive compensation and Company performance for the years listed below. As a smaller reporting company, we are permitted and have elected to provide scaled pay versus performance disclosure.

 

The following table summarizes the total Compensation Actually Paid to our principal executive officer (“PEO”) and our non-PEO named executive officers (“Non-PEO NEOs”), versus the performance of the Company for the fiscal years ended December 31, 2025, 2024 and 2023. The amounts below shown for Compensation Actually Paid have been calculated in accordance with SEC rules, do not represent the value of cash and equity awards received by our PEO and Non-PEO NEOs during the years and differ from compensation actually earned, realized or received by the individuals.

 

The calculation of Compensation Actually Paid begins with the information provided in the Summary Compensation Table for the individual (see page 22) and is adjusted as required by Item 402(v) of Regulation S-K, as noted in the footnotes below.

 

Fiscal Year

 

Summary Compensation Table Total for PEO ($)(1)

 

 

Compensation Actually Paid to PEO ($) (1)(5)

 

 

Average Summary Compensation Table Total for Non-PEO NEOs ($)(2)(3)(4)

 

 

Average Compensation Actually Paid to Non-PEOs ($)(2)(5)

 

 

Value of Initial $100 Investment Based on Total Shareholder Return ($)(6)

 

 

Net Income (Loss) ($)

 

2025

 

$614,000

 

 

$614,000

 

 

$213,542

 

 

$208,691

 

 

$158.54

 

 

$(3,748,995)

2024

 

$572,261

 

 

$572,261

 

 

$183,423

 

 

$183,423

 

 

$213.41

 

 

$(4,476,762)

2023

 

$689,635

 

 

$689,635

 

 

$303,588

 

 

$303,588

 

 

$205.28

 

 

$(3,402,592)

____________________________________ 

(1)

 Dr. Halden S. Shane served as our Principal Executive Officer (“PEO”) for each of the fiscal years ended December 31, 2025, 2024 and 2023. The amounts shown for Dr. Shane are derived from the Summary Compensation Table (“SCT”) for the applicable year.

 

 

(2)

The non-PEO Named Executive Officers included in the calculation for fiscal year 2025 were Elissa J. Shane, Nick Jennings and David Vanston. The non-PEO Named Executive Officers included in the calculation for fiscal year 2024 were Elissa J. Shane, Nick Jennings and Joseph Rzepka. The non-PEO Named Executive Officers included in the calculation for fiscal year 2023 were Elissa J. Shane and Nick Jennings.

 

 

(3)

The amounts reported represent the average Summary Compensation Table total compensation for the non-PEO Named Executive Officers identified in footnote (2) for the applicable fiscal year.

 

 

(4)

Harold Paul, who served as General Counsel during fiscal year 2024, was engaged as a consultant and not as an employee of the Company. Accordingly, Mr. Paul was not treated as a Named Executive Officer for purposes of the Summary Compensation Table or the Pay Versus Performance disclosure.

 

 

(5)

For the PEO, no adjustments were required to the amounts reported in the Summary Compensation Table in calculating Compensation Actually Paid (“CAP”). For the non-PEO Named Executive Officers, the 2025 CAP calculation includes the applicable adjustment for the unvested restricted stock units granted to David Vanston. Such unvested restricted stock units were valued as of December 31, 2025 in accordance with the applicable Pay Versus Performance requirements. The remaining unvested restricted stock units were subsequently forfeited and cancelled in 2026 following Mr. Vanston’s death.

 

 

(6)

Total Shareholder Return (“TSR”) represents the value of a hypothetical $100 investment in the Company’s Common Stock made on the last trading day of 2022, calculated through the end of each fiscal year presented. Historical share prices used in the calculation have been adjusted to reflect the Company’s 1-for-3 reverse stock split effective July 20, 2026.

 

 
26

Table of Contents

 

The below table shows the percentage changes in selected metrics from above.

 

Period

Compensation Actually Paid to PEO

Average Compensation Actually Paid to Non-PEO NEOs

Total Shareholder Return

Net Loss

2024 to 2025

Increased 7%

Increased 14%

Decreased 26%

Decreased 16%

2023 to 2024

Decreased 13%

Decreased 17%

Increased 4%

Increased 32%

 

Relationship between Compensation Actually Paid to our PEO and the Average of the Compensation Actually Paid to the Non-PEO NEOs and the Company’s Net Income. From 2024 through 2025, the compensation actually paid to our PEO increased 7% and the average compensation actually paid to the Non-PEO NEOs increased 14%, compared to a 16% decrease in our net loss over the same period. Net loss included in the Pay Versus Performance table is calculated in accordance with GAAP.

 

Total Shareholder Return. From 2024 to 2025, the total shareholder return decreased 26% from $213.41 to $158.54. We believe that our Total Shareholder Return was impacted significantly by certain short selling trading activities in the market outside of our control. The management believes strongly that the current and historical trading prices of our common stock do not reflect the actual valuation of the Company, and that our declining trading price was the result of active short selling by certain investors in the market beyond our control. While short selling may be permitted in some cases under applicable laws, we believe that certain investors, particularly those investing in small and microcap companies like TOMI, may be circumventing regulatory requirements and conducting aggressive short selling that is designed to drive down the trading price of our common stock, including naked short selling tactics.

 

For fiscal year 2025, Mr. Jennings served as Interim Chief Financial Officer through May 2025, and Mr. Vanston was appointed Chief Financial Officer effective May 30, 2025. Compensation actually paid to each is included in the average for the Non-PEO Named Executive Officers.

 

For fiscal year 2024, the Company had two individuals who served as Principal Financial Officer (CFO). Nick Jennings served from January 1, 2024 through May 14, 2024, and Joe Rzepka served from May 15, 2024 through December 15, 2024. On December 16, 2024, the Board appointed Nick Jennings as Interim Chief Financial Officer. In accordance with Item 402(v) of Regulation S-K, compensation actually paid to each individual who served as CFO during the year is included in the calculation of the average compensation actually paid to non-PEO Named Executive Officers.

 

Relationship between Compensation Actually Paid to our PEO and the Average of the Compensation Actually Paid to the Non-PEO NEOs and the Company’s Net Income. From 2023 through 2024, the compensation actually paid to our PEO decreased 13% and the average of the compensation actually paid to the Non-PEO NEOs decreased by 17%, compared to a 32% increase in our net loss over the same time period. Net loss included in the Pay Versus Performance table is calculated in accordance with GAAP.

 

Total Shareholder Return. From 2023 to 2024, the total shareholder return increased 4% from $205.28 to $213.41. We believe that our Total Shareholder Return was impacted significantly by certain short selling trading activities in the market outside of our control. The management believes strongly that the current and historical trading prices of our common stock do not reflect the actual valuation of the Company, and that our declining trading price was the result of active short selling by certain investors in the market beyond our control. While short selling may be permitted in some cases under applicable laws, we believe that certain investors, particularly those investing in small and microcap companies like TOMI, may be circumventing regulatory requirements and conducting aggressive short selling that is designed to drive down the trading price of our common stock, including naked short selling tactics.

 

 
27

Table of Contents

 

PROPOSAL 2:

RATIFICATION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

The Audit Committee, which consists of entirely independent directors, has selected Rosenberg Rich Baker Berman & Co. (“RRBB”) as our independent registered public accounting firm for the fiscal year ending December 31, 2026, and has further directed that management submit the selection of the independent registered public accounting firm for ratification, on a non-binding, advisory basis, by the shareholders at the Annual Meeting.

 

Representatives of RRBB are expected to be present at the Annual Meeting with the opportunity to make a statement if they desire to do so and are expected to be available to respond to appropriate questions.

 

Although ratification is not required by our Bylaws or otherwise, the Board is submitting the selection of RRBB as our independent registered public accounting firm to our shareholders for ratification as a matter of good corporate practice. No determination has been made as to what action the Board or the Audit Committee would take if shareholders do not ratify the appointment. Even if the appointment is ratified, however, the Audit Committee may, in its discretion, direct the appointment of a different independent registered public accounting firm at any time during the year if the Audit Committee determines that such a change would be in our best interests and the best interests of our shareholders.

 

Principal Accountant Fees and Services:

 

The following table shows the fees that were billed for audit and other services provided by RRBB during the 2025 and 2024 fiscal years:

 

 

 

For the Fiscal

Years Ended

December 31,

2025

 

 

For the Fiscal

Years Ended

December 31,

2024

 

Audit Fees(1)

 

$220,000

 

 

$162,500

 

Audit-Related Fees(2)

 

 

―

 

 

 

―

 

Tax Fees(3)

 

 

―

 

 

 

―

 

All Other Fees(4)

 

 

10,000

 

 

 

―

 

Total

 

$230,000

 

 

$162,500

 

 

(1)

Audit Fees: Audit fees represent the professional services rendered for the audit of our annual financial statements and the review of our financial statements included in quarterly reports, along with services normally provided by the accounting firm in connection with statutory and regulatory filings or engagements. Audit fees do not include fees for comfort letters or consents related to registration statements, which are reported separately under “All Other Fees.”

 

 

(2)

Audit-Related Fees: Audit-related fees represent professional services rendered for assurance and related services by RRBB that were reasonably related to the performance of the audit or review of our financial statements that are not reported under audit fees.

 

 

(3)

Tax Fees: Tax fees represent professional services rendered by the accounting firm for tax compliance, tax advice, and tax planning.

 

 

(4)

All Other Fees: For the year ended December 31, 2025, all other fees of $10,000 represent fees billed by RRBB for the issuance of comfort letters and consents in connection with the Company’s registration statement on Form S-3 (File No. 333-291563) declared effective December 8, 2025, and the related prospectus supplement filed pursuant to Rule 424(b)(5) in connection with the Company’s equity line of credit.

 

 
28

Table of Contents

 

Pre-Approval Policies and Procedures of the Audit Committee

 

Consistent with the rules and regulations promulgated by the SEC, the Audit Committee approves the engagement of our independent registered public accounting firm and is also required to pre-approve all audit and non-audit expenses. Prior to engaging its accountants to perform particular services, the Audit Committee obtains an estimate for the service to be performed. All of the services described above were approved by the Audit Committee in accordance with its procedure.

 

Vote Required

 

The affirmative vote of a majority of the votes cast by shareholders present or represented by proxy at the Annual Meeting and entitled to vote on this Proposal 2 is required for the approval thereof. Abstentions will have no effect on the outcome of this proposal.

 

Board Recommendation

 

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF ROSENBERG RICH BAKER BERMAN & CO. AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM.

 

 
29

Table of Contents

 

PROPOSAL 3

SAY-ON-PAY

 

The Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) and Section 14A of the Exchange Act requires public companies to hold a separate non-binding, advisory shareholders vote to approve the compensation of named executive officers as reported in this proxy statement (commonly known as the “Say-on-Pay” vote).

 

The vote on executive compensation is a non-binding, advisory vote on the compensation of our named executive officers, the tabular disclosure regarding such compensation, and the accompanying narrative disclosure, set forth in this proxy statement. The advisory vote on executive compensation is not a vote on our general compensation policies, the compensation of our Board, or our compensation policies as they relate to risk management.

 

The vote solicited by this Say-on-Pay Proposal is advisory, and therefore is not binding on the Company, our Board or our Compensation Committee. The outcome of the vote will not require the Company, our Board or our Compensation Committee to take any action, and will not be construed as overruling any decision by the Company or the Board.

 

Furthermore, because this non-binding, advisory resolution primarily relates to the compensation of our named executive officers that has already been paid or contractually committed, there is generally no opportunity for us to revisit these decisions. However, our Board, including our Compensation Committee, values the opinions of our shareholders, and will consider the outcome of the vote when making future compensation decisions for named executive officers.

 

Shareholders will be asked at the Annual Meeting to approve the following resolution pursuant to this Proposal 3:

 

RESOLVED, that the shareholders of the Company approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, disclosed pursuant to Item 402 of Regulation S-K in the Company’s definitive proxy statement for the 2026 Annual Meeting.

 

Vote Required

 

    Assuming that a quorum is present, the non-binding, advisory vote on the compensation of our named executive officers requires the affirmative vote of a majority of the votes cast by the shareholders present in person (virtually) or represented by proxy at the meeting. 

 

 This proposal is a “non-discretionary” (non-routine) matter under applicable stock exchange rules, meaning that if you are the beneficial owner of your shares and do not instruct your broker how to vote with respect to such proposal, your broker is not permitted to vote on such proposal and your votes will be counted as broker non-votes. Abstentions and broker non-votes will have no effect in determining the outcome of this proposal.

 

Board Recommendation

 

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL, ON A NON-BINDING, ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

 

 
30

Table of Contents

 

PROPOSAL 4:

TOMI ENVIRONMENTAL SOLUTIONS, INC. 2026 EQUITY INCENTIVE PLAN

 

We are asking our shareholders to approve a proposal to adopt the TOMI Environmental Solutions, Inc. 2026 Equity Incentive Plan (the “2026 EIP”), under which up to 3,500,000 shares of Common Stock will be reserved for issuance (subject to adjustments described below in the section titled “Adjustments”). 

 

The Board adopted the 2026 EIP on November 4, 2026, subject to shareholder approval at the Annual Meeting.  If approved by the shareholders, the 2026 EIP will become effective as of the date of the shareholder approval.

 

The 2026 EIP is a successor to the TOMI Environmental Solutions, Inc. Amended and Restated 2016 Equity Incentive Plan (the “Prior Plan”).  No additional grants shall be made under the Prior Plan following the expiration of its term on January 29, 2026.  Outstanding grants under the Prior Plan shall continue in effect according to their terms, consistent with the applicable terms of the Prior Plan.

 

Key Features of the 2026 EIP

 

The following features of the 2026 EIP will protect the interests of our shareholders:

 

 

·

No evergreen authorization: The 2026 EIP does not have an evergreen provision, which would have permitted an increase in the share pool without further shareholder approval.

 

 

 

 

·

Limitation on terms of stock options and stock appreciation rights: The maximum term of each stock option and stock appreciation right (SAR) is ten years.

 

 

 

 

·

No repricing or grant of discounted stock options or SARs: The 2026 EIP does not permit the repricing of stock options or SARs either by amending an existing grant or by substituting a new grant at a lower price.

 

 

 

 

·

No discounted options or SARs: The 2026 EIP prohibits the granting of stock options or SARs with an exercise price less than the fair market value of the Common Stock on the date of grant.

 

 

 

 

·

No liberal change-in-control definition: The 2026 EIP defines change of control based on the consummation of the transaction rather than the announcement or shareholder approval of the transaction.

 

 

 

 

·

No automatic vesting upon a change of control: Under the 2026 EIP, we do not automatically accelerate vesting of grants in connection with a change of control of the Company.

 

 

 

 

·

Limitation on dividends and dividend equivalents: We do not pay dividends or dividend equivalents on stock options or SARs. Dividend equivalents with respect to stock units or other stock-based awards that vest based on performance will vest only to the extent the grant actually becomes vested.

 

 

 

 

·

No tax gross-ups: The 2026 EIP does not provide for any tax gross-ups.

 

 

 

 

·

Clawback: Grants made under the 2026 EIP are subject to any applicable clawback or recoupment policies, share trading policies and other policies that may be implemented by the Board from time to time.

 

 

 

 

·

Limit on director pay: The 2026 EIP contains annual limits on the value of shares that may be granted to non-employee directors under the 2026 EIP.

 

 

 

 

·

Administered by an independent committee: The 2026 EIP is administered by the Compensation Committee of the Board, which consists entirely of independent directors. The Compensation Committee may delegate its authority to a subcommittee or officer, as described in more detail below.

 

 
31

Table of Contents

 

Summary of the 2026 EIP

 

The following is a summary of the material features of the 2026 EIP.  This summary is qualified in its entirety by reference to the complete text of the 2026 EIP, which is attached as Appendix A.  To the extent the description below differs from the text of the 2026 EIP, the text of the 2026 EIP shall control.

 

Types of Grants

 

The 2026 EIP provides for the issuance of stock options (including nonqualified stock options and incentive stock option), stock appreciation rights (referred to as “SARs”), stock awards, stock units, and other stock-based awards to officers, employees, non-employee directors, consultants and advisors of the Company or its subsidiaries.

 

Administration

 

The 2026 EIP is administered by the Compensation Committee of the Board, except that grants to members of the Board must be authorized by a majority of the Board.  Our Compensation Committee may delegate authority under the 2026 EIP to one or more subcommittees as it deems appropriate.  

 

Subject to compliance with applicable law and stock exchange requirements, the Compensation Committee (or the Board or a subcommittee, as applicable) may delegate all or part of its authority to our Chief Executive Officer, as it deems appropriate, with respect to grants to employees or key advisors who are not executive officers or directors under Section 16 of the Securities Exchange Act of 1934, as amended.  

 

Our Compensation Committee, the Board, any subcommittee or the Chief Executive Officer, as applicable, that has authority with respect to a specific grant will be referred to as “the committee” in this description of the 2026 EIP.

 

Eligibility

 

All of our employees are eligible to receive grants under the 2026 EIP.  In addition, our non-employee directors and consultants and advisors who perform services for us may receive grants under the 2026 EIP.  As of October 30, 2026, we had approximately 17 employees (including 3 executive officers) and 3 non-employee directors eligible to participate in the 2026 EIP.

 

Shares Subject to the Plan

 

Subject to adjustment, the 2026 EIP currently authorizes the issuance or transfer of up to 3,500,000 shares of Common Stock.  In addition, shares of Common Stock underlying any outstanding grant made under the Prior Plan that, following the effective date of the 2026 EIP, expires, or is terminated, surrendered or forfeited for any reason without issuance of such shares shall be available for new grants under the 2026 EIP.  The aggregate number of shares of Common Stock that may be issued or transferred under the 2026 EIP pursuant to incentive stock options under Section 422 of the Internal Revenue Code (the “Code”) may not exceed 3,500,000 shares.

 

If any options or SARs expire or are canceled, forfeited, exchanged or surrendered without having been exercised, or if any stock awards, stock units or other stock-based awards are forfeited, terminated or otherwise not paid in full, the shares of Common Stock subject to such grants will again be available for purposes of the 2026 EIP.  If shares of Common Stock are surrendered in payment of the exercise price of an option, the number of shares of Common Stock available for issuance under the 2026 EIP will be reduced only by the net number of shares actually issued by us upon such exercise and not by the gross number of shares as to which such option is exercised.  Upon the exercise of any SAR under the 2026 EIP, the number of shares of Common Stock available for issuance will be reduced only by the net number of shares actually issued by us upon such exercise.

 

 
32

Table of Contents

 

If shares of Common Stock are withheld by us in satisfaction of the withholding taxes incurred in connection with the issuance, vesting or exercise of any grant or the issuance of Common Stock under the 2026 EIP, the number of shares of Common Stock available for issuance will be reduced by the net number of shares issued, vested or exercised under such grant, calculated in each instance after payment of such share withholding.  If any grants are paid in cash, and not in shares of Common Stock, any shares of Common Stock subject to such grants will also be available for future grants under the EIP.  If we repurchase shares of Common Stock on the open market with the proceeds from the exercise price we receive from options, the repurchased shares will not be available for issuance under the 2026 EIP.

 

Adjustments

 

In connection with stock splits, stock dividends, recapitalizations and certain other events affecting Common Stock, the committee will make adjustments as it deems appropriate in: (a) the maximum number and kind of shares of Common Stock reserved for issuance as grants; (b) the maximum number and kind of shares of Common Stock that may be issued as incentive stock options; (c) the maximum value of grants that may be granted to any individual non-employee director in any year; (d) the number and kind of shares and the exercise, purchase or base price per share in effect under each outstanding grant; and (e) such other terms and conditions for outstanding grants as the committee deems appropriate.

 

Grants

 

The committee has complete discretion to (a) determine which eligible individuals are to receive grants under the 2026 EIP, (b) determine the type, size, terms and conditions of the grants to be made, (c) determine the time when those grants are to be made and any exercise or restriction period, (d) amend any previously issued grant, subject to the provisions of the 2026 EIP, (e) determine the terms, guidelines and provisions that apply to grants to individuals residing outside of the United States, consistent with the terms of the 2026 EIP and applicable law, (f) deal with any other matters rising under the 2026 EIP, and (h) take any action authorized under the 2026 EIP in connection with a change in control.

 

Options

 

Each option granted under the 2026 EIP will have an exercise price per share determined by the committee, but the exercise price will not be less than the fair market value of a share of Common Stock on the date the option is granted.  If an incentive stock option is granted to a 10% shareholder of the total combined voting power of all classes of our stock, the exercise price cannot be less than 110% of the fair market value of a share of Common Stock on the date the option is granted.  

 

No option will have a term in excess of ten years, except that if an incentive stock option is granted to a 10% shareholder of the total combined voting power of all class of our stock, the term cannot exceed five years from the date of grant.

 

The shares subject to each option will generally vest in one or more installments over a specified period of service measured from the grant date or upon the achievement of pre-established performance objectives.  

 

Payment of the exercise price may be paid in one or more of the following forms as determined by the committee: cash, shares of Common Stock, through a cashless exercise procedure pursuant to which the optionee effects a same-day exercise of the option and sale of the purchased shares through a broker in order to cover the exercise price for the purchased shares and the applicable withholding taxes, through a net exercise procedure pursuant to which we withhold a number of shares otherwise issuable upon exercise of the option having a value equal to the exercise price and applicable withholding taxes and/or by such other method as approved by the committee.

 

In the event that on the last day of the term of a nonqualified stock option, the exercise is prohibited by applicable law, including a prohibition on purchases or sales of Common Stock under our insider trading policy, the term of the nonqualified option will be extended for a period of 30 days following the end of the legal prohibition, unless the committee determines otherwise.

 

 
33

Table of Contents

 

Except as provided in the grant instrument, an option may only be exercised while a participant is employed by or providing service to us.  The committee will determine in the grant instrument under what circumstances and during what time periods a participant may exercise an option after termination of employment.

 

Stock Awards

 

Under the 2026 EIP, the committee may grant stock awards.  A stock award is a grant of Common Stock that may be subject to restrictions as the committee determines.  The restrictions, if any, may lapse over a specified period of employment or based on the satisfaction of pre-established criteria, in installments or otherwise, as the committee may determine, including, but not limited to, restrictions based on the achievement of performance goals.  

 

Except to the extent restricted under the grant instrument relating to the stock award, a participant will have all of the rights of a shareholder as to those shares, including the right to vote and the right to receive dividends or distributions on the shares.  Dividends with respect to stock awards that vest based on performance shall vest if and to the extent that the underlying stock award vests, as determined by the committee.  

 

All unvested stock awards are forfeited if the participant’s employment or service is terminated for any reason, unless the committee determines otherwise.

 

Stock Units

 

Under the 2026 EIP, the committee may grant stock units to anyone eligible to participate in the 2026 EIP.  Stock units represent hypothetical shares of Common Stock.  Stock units become payable on terms and conditions determined by the committee, including specified performance goals, and will be payable in cash, shares of Common Stock, or a combination thereof, as determined by the committee.  All unvested stock units are forfeited if the participant’s employment or service is terminated for any reason, unless the committee determines otherwise.

 

Stock Appreciation Rights

 

Under the 2026 EIP, the committee may grant SARs, which may be granted separately or in tandem with any option.  SARs granted in tandem with a nonqualified stock option may be granted either at the time the nonqualified stock option is granted or any time thereafter while the option remains outstanding.  SARs granted in tandem with an incentive stock option may be granted only at the time the grant of the incentive stock option is made.  The committee will establish the base amount of the SAR at the time the SAR is granted, which will be equal to or greater than the fair market value of a share of Common Stock as of the date of grant.

 

If a SAR is granted in tandem with an option, the number of SARs that are exercisable during a specified period will not exceed the number of shares of Common Stock that the participant may purchase upon exercising the related option during such period.  Upon exercising the related option, the related SARs will terminate, and upon the exercise of a SAR, the related option will terminate to the extent of an equal number of shares of Common Stock.  Generally, SARs may only be exercised while the participant is employed by or providing services to us.  When a participant exercises a SAR, the participant will receive the excess of the fair market value of the underlying Common Stock over the base amount of the SAR.  The appreciation of a SAR will be paid in shares of Common Stock, cash or both.

 

The term of a SAR cannot exceed ten years from the date of grant.  In the event that on the last day of the term of a SAR, the exercise is prohibited by applicable law, including a prohibition on purchases or sales of Common Stock under our insider trading policy, the term of the SAR will be extended for a period of 30 days following the end of the legal prohibition, unless the committee determines otherwise.

 

Other Stock-Based Awards

 

Under the 2026 EIP, the committee may grant other types of awards, which are based on, or measured by, Common Stock, to anyone eligible to participate in the 2026 EIP.  The committee will determine the terms and conditions of such awards.  Other stock-based awards may be payable in cash, shares of Common Stock or a combination of the two, as determined by the committee.

 

 
34

Table of Contents

 

Dividend Equivalents

 

Under the 2026 EIP, the committee may grant dividend equivalents in connection with grants of stock units or other stock-based awards made under the 2026 EIP.  Dividend equivalents entitle the participant to receive amounts equal to ordinary dividends that are paid on the shares underlying a grant while the grant is outstanding.  The committee will determine whether dividend equivalents will be paid currently or accrued as contingent cash obligations.

 

Dividend equivalents may be paid in cash or shares of Common Stock.  The committee will determine the terms and conditions of the dividend equivalent grants, including whether the grants are payable upon the achievement of specific performance goals.  Dividend equivalents with respect to stock units or other stock-based awards that vest based on performance shall vest and be paid only if and to the extent that the underlying stock units or other stock-based awards vest and are paid as determined by the committee.

 

Prohibition on Repricing

 

Under the terms of the 2026 EIP, the committee may not (i) amend the terms of any outstanding stock options or SARs to reduce the exercise price or base price, as applicable, (ii) cancel outstanding stock options or SARs in exchange for stock options or SARs with an exercise price or base price, as applicable, that is less than the exercise price or base price of the original stock options or SARs or (iii) cancel outstanding stock options or SARs with an exercise price or base price, as applicable, above the current stock price in exchange for cash or other securities, except in connection with a corporate transaction involving the Company, without in each such instance obtaining the approval of our shareholders.

 

Change of Control

 

If we experience a change of control where we are not the surviving corporation (or survive only as a subsidiary of another corporation), unless the committee determines otherwise, all outstanding grants that are not exercised or paid at the time of the change of control will be assumed by, or replaced with grants (with respect to cash, securities or a combination thereof) that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation).

 

If there is a change of control and all outstanding grants are not assumed by, or replaced with grants that have comparable terms by the surviving corporation, the committee may (but is not obligated to) make adjustments to the terms and conditions of outstanding grants, including, without limitation, taking any of the following actions (or combination thereof) without the consent of any participant:

 

 

·

determine that outstanding options and SARs will accelerate and become fully exercisable and the restrictions and conditions on outstanding stock awards, stock units and dividend equivalents immediately lapse;

 

 

 

 

·

pay participants, in an amount and form determined by the committee, in settlement of outstanding stock units, other stock-based awards or dividend equivalents;

 

 

 

 

·

require that participants surrender their outstanding stock options and SARs in exchange for a payment by us, in cash or shares of Common Stock, equal to the difference between the exercise price and the fair market value of the underlying shares of Common Stock; provided, however, if the per share fair market value of Common Stock does not exceed the per share stock option exercise price or SAR base amount, as applicable, we will not be required to make any payment to the participant upon surrender of the stock option or SAR; or

 

 

 

 

·

after giving participants an opportunity to exercise all of their outstanding stock options and SARs, terminate any unexercised stock options and SARs on the date determined by the committee.

 

 

 

 

 
35

Table of Contents

 

 

 

In general terms, a change of control under the 2026 EIP occurs if:

 

 

 

 

·

a person, entity or affiliated group, with certain exceptions, acquires more than 50% of our then- outstanding voting securities;

 

 

 

 

·

we merge into another entity unless the holders of our voting shares immediately prior to the merger have at least 50% of the combined voting power of the securities in the merged entity or its parent;

 

 

 

 

·

we merge into another entity and the members of the Board prior to the merger would not constitute a majority of the board of the merged entity or its parent;

 

 

 

 

·

we sell or dispose of all or substantially all of our assets;

 

 

 

 

·

we consummate a complete liquidation or dissolution; or

 

 

 

 

·

a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the incumbent directors.

 

The committee shall have the authority to provide that any escrow, holdback, earn-out or similar provisions in the definitive agreement effecting the change of control shall apply to any cash payment made as described above, to the same extent and in the same manner as such provisions apply to a holder of a share of Company Stock.

 

Deferrals

 

The committee may permit or require participants to defer receipt of the payment of cash or the delivery of shares of Common Stock that would otherwise be due to the participant in connection with a grant under the 2026 EIP.  The committee will establish the rules and procedures applicable to any such deferrals, consistent with the requirements of Section 409A of the Code.

 

New Plan Benefits

 

No grants have been made under the 2026 EIP.  Any grants made following approval of this proposal shall be at the discretion of the committee.  Accordingly, the benefits or amounts that may be received by or allocated to any of our executive officers, employees, non-employee directors and nominees for election as a director are not determinable at this time.

 

 Valuation

 

The fair market value per share of Common Stock on any relevant date under the 2026 EIP is deemed to be equal to the closing selling price per share on that date as determined on the Nasdaq. As of November 10, 2026, the fair market value of a share of Common Stock determined on such basis was $2.63 per share.

 

Withholding

 

All grants under the 2026 EIP are subject to applicable U.S. federal (including FICA), state and local, foreign or other tax withholding requirements.  We may require participants or other persons receiving grants or exercising grants to pay an amount sufficient to satisfy such tax withholding requirements with respect to such grants, or we may deduct from other wages and compensation paid by us the amount of any withholding taxes due with respect to such grant.

 

The committee may permit or require that our tax withholding obligation with respect to grants paid in Common Stock be paid by having shares withheld up to an amount that does not exceed the participant’s minimum applicable withholding tax rate for United States federal (including FICA), state and local, foreign or other tax liabilities, or as otherwise determined by the committee.  In addition, the committee may, in its discretion, and subject to such rules as the committee may adopt, allow participants to elect to have such share withholding applied to all or a portion of the tax withholding obligation arising in connection with any particular grant.

 

 
36

Table of Contents

 

Transferability

 

Except as permitted by the committee with respect to nonqualified stock options, only a participant may exercise rights under a grant during the participant’s lifetime.  Upon death, the personal representative or other person entitled to succeed to the rights of the participant may exercise such rights.  A participant cannot transfer those rights except by will or by the laws of descent and distribution or, with respect to grants other than incentive stock options, pursuant to a domestic relations order.  The committee may provide in a grant instrument that a participant may transfer nonqualified stock options and stock award to family members, or one or more trusts or other entities for the benefit of, or owned by, family members, consistent with applicable securities laws and such terms as determined by the committee.

 

Requirements for Issuance of Shares

 

No Common Stock will be issued or transferred in connection with any grant unless and until all legal requirements applicable to the issuance or transfer of such Common Stock have been complied with to the satisfaction of the committee.  The committee has the right to condition any grant on the participant’s undertaking in writing to comply with such restrictions on the participant’s subsequent disposition of the shares of Common Stock as the committee deems necessary or advisable.

 

Amendment; Termination

 

The Board may amend or terminate the 2026 EIP at any time, except that our shareholders must approve an amendment if such approval is required in order to comply with the Code, applicable laws or applicable stock exchange requirements.  Unless terminated sooner by the Board or extended with shareholder approval, the 2026 EIP will terminate on the day immediately preceding the tenth anniversary of the effective date of the 2026 EIP.

 

Shareholder Approval

 

Except in connection with certain corporate transactions, including stock dividends, stock splits, a recapitalization, a change of control, a reorganization, a merger and a spin-off, shareholder approval is required (i) to reduce the exercise price or base price of outstanding stock options or SARs, (ii) to cancel outstanding stock options or SARs in exchange for the same type of grant with a lower exercise price or base price, and (iii) to cancel outstanding stock options or SARs that have an exercise price or base price above the current price of a share of Common Stock, in exchange for cash or other securities.

 

Establishment of Sub-Plans

 

The Board may, from time to time, establish one or more sub-plans under the 2026 EIP to satisfy applicable blue sky, securities or tax laws of various jurisdictions.  The Board may establish such sub-plans by adopting supplements to the 2026 EIP setting forth limitations on the committee’s discretion and such additional terms and conditions not otherwise inconsistent with the 2026 EIP as the Board deems necessary or desirable.  All such supplements will be deemed part of the 2026 EIP, but each supplement will only apply to participants within the affected jurisdiction, and we will not be required to provide copies of any supplement to such unaffected participants.

 

Clawback

 

Subject to applicable law, the committee may provide in any grant instrument that if a participant breaches any restrictive covenant agreement between the participant and us, or otherwise engages in activities that constitute cause (as defined in the 2026 EIP) either while employed by or providing services to us or within a specified period of time thereafter, all grants held by the participant will terminate, and we may rescind any exercise of an option or SAR and the vesting of any other grant and delivery of shares upon such exercise or vesting, as applicable on such terms as the committee will determine, including the right to require that in the event of any rescission:

 

 

·

the participant must return the shares received upon the exercise of any option or SAR or the vesting and payment of any other grants; or

 

 

 

 

·

if the participant no longer owns the shares, the participant must pay to us the amount of any gain realized or payment received as a result of any sale or other disposition of the shares (if the participant transferred the shares by gift or without consideration, then the fair market value of the shares on the date of the breach of the restrictive covenant agreement or activity constituting cause), net of the price originally paid by the participant for the shares.

 

 
37

Table of Contents

 

The committee may also provide for clawbacks pursuant to a clawback policy, which the Board may in the future adopt and amend from time to time.  Payment by the participant will be made in such manner and on such terms and conditions as may be required by the committee.  We will be entitled to set off against the amount of any such payment any amounts that we otherwise owe to the participant.

 

Summary of U.S. Federal Income Tax Consequences

 

The following is a summary of the U.S. federal income taxation treatment applicable to us and the participants who receive awards under the 2026 EIP.

 

Option Grants.  Options granted under the 2026 EIP may be either incentive options, which satisfy the requirements of Section 422 of the Code, or nonqualified options, which are not intended to meet such requirements.  The federal income tax treatment for the two types of options differs as follows:

 

Incentive Options.  No taxable income is recognized by the optionee at the time of the option grant, and no taxable income is recognized for regular tax purposes at the time the option is exercised, although taxable income may arise at that time for alternative minimum tax purposes.  The optionee will recognize taxable income in the year in which the purchased shares are sold or otherwise made the subject of certain other dispositions.  For Federal tax purposes, dispositions are divided into two categories: (i) qualifying, and (ii) disqualifying.  A qualifying disposition occurs if the sale or other disposition is made more than two (2) years after the date the option for the shares involved in such sale or disposition is granted and more than one (1) year after the date the option is exercised for those shares.  If the sale or disposition occurs before these two periods are satisfied, then a disqualifying disposition will result.

 

Upon a qualifying disposition, the optionee will recognize long-term capital gain in an amount equal to the excess of (i) the amount realized upon the sale or other disposition of the purchased shares over (ii) the exercise price paid for the shares.  If there is a disqualifying disposition of the shares, then the excess of (i) the fair market value of those shares on the exercise date or (if less) the amount realized upon such sale or disposition over (ii) the exercise price paid for the shares will be taxable as ordinary income to the optionee.  Any additional gain or loss recognized upon the disposition will be a capital gain or loss.

 

If the optionee makes a disqualifying disposition of the purchased shares, then we will be entitled to an income tax deduction, for the taxable year in which such disposition occurs, equal to the amount of ordinary income recognized by the optionee as a result of the disposition.  We will not be entitled to any income tax deduction if the optionee makes a qualifying disposition of the shares.

 

Nonqualified Options.  No taxable income is recognized by an optionee upon the grant of a nonqualified option.  The optionee will in general recognize ordinary income, in the year in which the option is exercised, equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares, and the optionee will be required to satisfy the tax withholding requirements applicable to such income.  We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the optionee with respect to the exercised nonqualified option.  The deduction will in general be allowed for our taxable year in which such ordinary income is recognized by the optionee.

 

Stock Appreciation Rights.  No taxable income is recognized upon receipt of a SAR.  The holder will recognize ordinary income in the year in which the SAR is exercised, in an amount equal to the excess of the fair market value of the underlying shares on the exercise date over the base price in effect for the exercised right, and the holder will be required to satisfy the tax withholding requirements applicable to such income.  We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the holder in connection with the exercise of the SAR.  The deduction will be allowed for the taxable year in which such ordinary income is recognized.

 

Stock Awards.  The recipient of unvested shares of Common Stock issued under the 2026 EIP will not recognize any taxable income at the time those shares are issued but will have to report as ordinary income, as and when those shares subsequently vest, an amount equal to the excess of (i) the fair market value of the shares on the vesting date over (ii) the cash consideration (if any) paid for the shares.  The recipient may, however, elect under Section 83(b) of the Code to include as ordinary income in the year the unvested shares of Common Stock are issued an amount equal to the excess of (i) the fair market value of those shares on the issue date over (ii) the cash consideration (if any) paid for such shares.  If the Section 83(b) election is made, the recipient will not recognize any additional income as and when the shares subsequently vest.  We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the recipient with respect to the unvested shares.  The deduction will in general be allowed for our taxable year in which such ordinary income is recognized by the recipient.

 

 
38

Table of Contents

 

Stock Units.  No taxable income is recognized upon receipt of restricted stock units.  The holder will recognize ordinary income in the year in which the shares subject to the units are issued to the holder.  The amount of that income will be equal to the fair market value of the shares on the date of issuance, and the holder will be required to satisfy the tax withholding requirements applicable to such income.  We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the holder at the time the shares are issued.  The deduction will be allowed for the taxable year in which such ordinary income is recognized.

 

Dividend Equivalent Rights.  No taxable income is recognized upon receipt of a dividend equivalent right award.  The holder will recognize ordinary income in the year in which a dividend or distribution, whether in cash, securities, or other property, is paid to the holder.  The amount of that income will be equal to the fair market value of the cash, securities or other property received, and the holder will be required to satisfy the tax withholding requirements applicable to such income.  We will be entitled to an income tax deduction equal to the amount of the ordinary income recognized by the holder of the dividend equivalent right award at the time the dividend or distribution is paid to such holder.  That deduction will be allowed for the taxable year in which such ordinary income is recognized.

 

Other Stock-Based Awards.  In general, no taxable income is recognized upon receipt of other awards.  The holder will recognize ordinary income in the year in which the awards are settled, and the participant will be required to satisfy the tax withholding requirements applicable to such income.  We will be entitled to an income tax deduction equal to the amount of ordinary income recognized by the participant at the time of settlement.  The deduction will be allowed for the taxable year in which such ordinary income is recognized.

 

Vote Required

 

The affirmative vote of a majority of the votes cast by shareholders present or represented by proxy at the Annual Meeting and entitled to vote on this Proposal 4 is required for the approval thereof. Abstentions will have no effect on the outcome of this proposal.

 

Board Recommendation

 

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF THE COMPANY’S 2026 EQUITY INCENTIVE PLAN.

 

 
39

Table of Contents

 

PROPOSAL 5A:

 

APPROVAL OF PREFERRED STOCK CHARTER AMENDMENT

 

The Board has approved and recommended that shareholders approve an amendment to the Company’s Articles of Incorporation to, among other things, authorize the issuance of 10,000,000 shares of “blank check” preferred stock (the “Preferred Stock Charter Amendment”). The form of the Preferred Stock Charter Amendment is included in Appendix B attached to this proxy statement.

 

Purpose of the “Blank Check” Preferred Stock

 

We believe that for us to successfully execute our business strategy we will need to raise investment capital and it may be preferable or necessary to issue preferred stock to investors. Preferred stock may grant the holders certain preferential rights in voting, dividends, liquidation or other rights in preference over a company’s common stock. Accordingly, in order to grant us the flexibility to issue our equity securities in the manner best suited for our Company, or as may be required by the capital markets, the Preferred Stock Charter Amendment will authorize 10,000,000 authorized shares of “blank check” preferred stock.

 

The term “blank check” refers to preferred stock, the creation and issuance of which is authorized in advance by our shareholders and the terms, rights and features of which are determined by our Board upon issuance. The authorization of such “blank check” preferred stock permits our Board to authorize and issue preferred stock from time to time in one or more series without seeking further action or vote of our shareholders. 

 

Principal Effects of the “Blank Check” Preferred Stock

 

Subject to the limitations prescribed by Florida law, the Board would be expressly authorized, at its discretion, to adopt resolutions to issue shares, to fix the number of shares and to change the number of shares constituting any series and to provide for or change the voting powers, designations, preferences and relative, participating, optional or other special rights, qualifications, limitations or restrictions thereof, including dividend rights (including whether the dividends are cumulative), dividend rates, terms of redemption, redemption prices, conversion rights and liquidation preferences of the shares constituting any series of the preferred stock, in each case without any further action or vote by our shareholders. The Board would be required to make any determination to issue shares of preferred stock based on its judgment as to what is in our best interests and the best interests of our shareholders.

 

The authorization of the “blank check” preferred stock will provide us with increased financial flexibility in meeting future capital requirements. It will allow preferred stock to be available for issuance from time to time and with such features as determined by our Board for any proper corporate purpose. It is anticipated that such purposes may include, without limitation, exchanging preferred stock for common stock, the issuance for cash as a means of obtaining capital for our use, issuance as part or all of the consideration required to be paid by us for acquisitions of other businesses or assets, or issuance as part or all of an equity compensation plan.

 

The issuance by us of preferred stock could dilute both the equity interests and the earnings per share of existing holders of the common stock. Such dilution may be substantial, depending upon the number of shares issued. The newly authorized shares of preferred stock could also have voting rights superior to our common stock, and in such event would have a dilutive effect on the voting power of our existing shareholders.

 

Any issuance of preferred stock with voting rights could, under certain circumstances, have the effect of delaying or preventing a change in control of the Company by increasing the number of outstanding shares entitled to vote and by increasing the number of votes required to approve a change in control of the Company. Shares of voting or convertible preferred stock could be issued, or rights to purchase such shares could be issued, to render more difficult or discourage an attempt to obtain control of the Company by means of a tender offer, proxy contest, merger or otherwise. Such issuances could therefore deprive our shareholders of benefits that could result from such an attempt, such as the realization of a premium over the market price that such an attempt could cause. Moreover, the issuance of such shares of preferred stock to persons friendly to our Board could make it more difficult to remove incumbent managers and directors from office even if such change were to be favorable to shareholders generally.

 

Vote Required

 

The affirmative vote of a majority of the votes cast by shareholders present or represented by proxy at the Annual Meeting and entitled to vote on this Proposal 5A is required for the approval thereof. Abstentions will have no effect on the outcome of this proposal.

 

Board Recommendation

 

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF THE PREFERRED STOCK CHARTER AMENDMENT.

 

 
40

Table of Contents

 

PROPOSAL 5B:

 

APPROVAL OF QUORUM CHARTER AMENDMENT

 

We are proposing to amend our Articles of Incorporation to authorize our Board to establish and modify from time to time the quorum requirements for meetings of shareholders, subject to applicable law and Nasdaq rules (the “Quorum Charter Amendment”). Our current quorum requirement for shareholder meetings is a majority of the votes entitled to be cast. The Board has approved the Quorum Charter Amendment and recommends its approval by shareholders. The form of the Quorum Charter Amendment is included in Appendix B attached to this proxy statement.

 

Purpose and Effect of the Amendment

 

The purpose of this Proposal 5B is to provide greater flexibility in achieving a quorum at future shareholder meetings, including annual meetings.

 

Under the Florida Business Corporation Act (the “FBCA”), a quorum generally requires the presence in person or by proxy of shareholders holding a majority of the votes entitled to be cast, unless the Articles of Incorporation establish a different quorum requirement, subject to applicable statutory limitations.

 

If the Company fails to achieve a quorum at a shareholder meeting, the meeting may need to be postponed or adjourned, resulting in additional costs and delays associated with soliciting proxies and conducting the meeting. The Board believes that greater flexibility in establishing quorum requirements would reduce these risks and facilitate the Company’s ability to conduct business requiring shareholder approval.

 

If approved, the Quorum Charter Amendment would authorize the Board to establish and modify the quorum requirements through amendments to the Company’s Bylaws, provided that such requirements are not less than the minimum prescribed by the FBCA and otherwise comply with Nasdaq rules. The Quorum Charter Amendment would not by itself change the existing quorum requirement, which would remain in effect unless and until modified by the Board.

 

Risks Related to the Amendment

 

Although the Quorum Charter Amendment is intended to facilitate the conduct of future shareholder meetings, any reduction in the quorum requirement could permit a smaller percentage of shareholders to be represented at meetings and participate in decisions affecting the Company. Consequently, corporate actions could be approved with fewer shares represented than would be required under the current quorum requirement.

 

The Quorum Charter Amendment would not change the voting thresholds applicable to the approval of particular matters under applicable law or the Company’s Articles of Incorporation.

 

If shareholders do not approve the Quorum Charter Amendment, the Company’s existing quorum requirement will remain in effect.

 

Vote Required

 

The affirmative vote of a majority of the votes cast by shareholders present or represented by proxy at the Annual Meeting and entitled to vote on this Proposal 5B is required for the approval thereof. Abstentions will have no effect on the outcome of this proposal.

 

Board Recommendation

 

THE BOARD UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF THE QUORUM CHARTER AMENDMENT.

 

 
41

Table of Contents

 

OTHER MATTERS

 

The Board and management do not know of any other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly brought before the Annual Meeting, the Proxy Holder will vote on such matters in accordance with his or her best judgment.

 

SHAREHOLDER PROPOSALS FOR 2027 ANNUAL MEETING

 

To be considered for inclusion in next year’s Proxy Statement, shareholder proposals must be received at our principal executive offices no later than the close of business on [●], 2027, in accordance with Rule 14a-8 promulgated under the Exchange Act. However, if the date of the next annual meeting is changed by more than 30 days from the anniversary of this year’s Annual Meeting, then, to be considered for inclusion in the Proxy Statement relating to next year’s annual meeting, notice of a shareholder proposal will need to be received by us in a reasonable amount of time before we begin to send our proxy materials for the 2027 annual meeting.

 

If a shareholder wishes to present a shareholder proposal at our next annual meeting that is not intended to be included in the Proxy Statement, we must receive such proposal within a reasonable time before we begin to print and send our proxy materials in connection with such annual meeting. Under Rule 14a-4(c) under the Exchange Act, which governs our use of discretionary proxy voting authority with respect to shareholder proposals that are not included in our proxy solicitation materials pursuant to Rule 14a-8 of the Exchange Act, if we do not receive the shareholder’s notice of intent to present such a proposal at our 2027 annual meeting within a reasonable time before we begin to print and send our proxy materials in connection with such annual meeting, then our management proxies will have the right to exercise their discretionary authority in connection with the matter submitted by the shareholders, without discussion of the matter in the Proxy Statement. However, if the date of our 2027 annual meeting is changed by more than 30 days from the anniversary of this year’s Annual Meeting, then notice will need to be received by us not earlier than the close of business on the 90th day prior to such annual meeting and not later than the close of business on the later of the 60th day prior to such annual meeting or, in the event public announcement of the date of such annual meeting is first made by us fewer than 70 days prior to the date of such annual meeting, the close of business on the 10th day following the day on which we made the first public announcement of the date of such meeting.

 

In addition to satisfying the foregoing advance notice requirements under the Bylaws, to comply with the universal proxy rules under the Exchange Act, shareholders who intend to solicit proxies in support of director nominee other than TOMI’s nominees for the 2027 annual meeting must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no later than October 19, 2027. However, if the date of the 2027 annual meeting of shareholders is more than 30 calendar days before or more than 30 calendar days after the anniversary date of the Annual Meeting, such information must be provided by the later of the 60th day prior to such annual meeting and the 10th day following the public announcement of the date of such meeting.

 

Any proposal must comply with the requirements as to form and substance established by the SEC for such proposal to be included in our Proxy Statement. We reserve the right to exclude shareholder proposals pursuant to SEC rules, or if untimely. If a shareholder nominates a director candidate, in order for such nomination to be valid and acceptable, all information required to be provided under Regulation 14A under the Exchange Act and requested by the Board concerning such candidate must be furnished within a reasonable time prior to the above deadline for shareholder proposals.

 

All notices of intention to present a proposal at the 2027 annual meeting should be addressed to TOMI Environmental Solutions, Inc., 8430 Spires Way, Frederick, Maryland 21701, Attention: Chief Executive Officer, and to ensure prompt receipt by us, such notices should be sent to us via certified mail, return receipt requested. We reserve the right to reject, rule out of order, or take other appropriate action with respect to any proposal that does not comply with these and other applicable requirements. Any shareholder proposal for next year’s annual meeting submitted after the deadlines described above will not be considered filed on a timely basis. For proposals that are not timely filed, we retain discretion to vote the proxies we receive. For proposals that are timely filed, we retain discretion to vote the proxies we receive, provided that (i) we include in our Proxy Statement advice on the nature of the proposal and how we intend to exercise our voting discretion and (ii) the proponent does not issue a Proxy Statement.

 

 
42

Table of Contents

 

DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS

 

The SEC has adopted rules that permit companies and intermediaries such as brokers to satisfy delivery requirements for Proxy Statements with respect to two or more shareholders sharing the same address by delivering a single Proxy Statement addressed to those shareholders. This process, which is commonly referred to as “householding,” potentially provides extra convenience for shareholders and cost savings for companies. We and some brokers deliver a single Proxy Statement to multiple shareholders sharing an address unless contrary instructions have been received from the affected shareholders. Once you have received notice from your broker or us that they are or we will be householding materials to your address, householding will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in householding and would prefer to receive a separate Proxy Statement, or if you currently receive multiple Proxy Statements and would prefer to participate in householding, please notify your broker if your shares are held in a brokerage account or us if you hold registered shares. You can notify us by sending a written request to TOMI Environmental Solutions, Inc., 8430 Spires Way, Frederick, Maryland 21701, Attention: Chief Executive Officer, or by calling our investor relations department at (800) 525-1698.

 

IMPORTANT

 

Your vote at this year’s Annual Meeting is important, no matter how many or how few shares of Voting Stock you own. Please sign and date the enclosed proxy card and return it in the enclosed postage-paid envelope promptly.

 

Only your latest dated, signed proxy card will be counted. Any proxy may be revoked at any time prior to its exercise at the Annual Meeting as described in this Proxy Statement.

 

 
43

Table of Contents

 

APPENDIX A

 

TOMI ENVIRONMENTAL SOLUTIONS, INC.

 

2026 EQUITY INCENTIVE PLAN

 

Effective as of the Effective Date (as defined below), the TOMI Environmental Solutions, Inc. 2026 Equity Incentive Plan (as in effect from time to time, the “Plan”) is hereby established.

 

The purpose of the Plan is to provide employees of the Company and its subsidiaries, certain consultants and advisors who perform services for the Company or its subsidiaries, and non-employee members of the Board of Directors of the Company, with the opportunity to receive grants of incentive stock options, nonqualified stock options, stock appreciation rights, stock awards, stock units, and other stock-based awards.

 

The Company believes that the Plan will encourage the participants to contribute materially to the growth of the Company, thereby benefitting the Company’s stockholders, and will align the economic interests of the participants with those of the stockholders.

 

The Plan is a successor to the TOMI Environmental Solutions, Inc. Amended and Restated 2016 Equity Incentive Plan (the “Prior Plan”). No additional grants shall be made under the Prior Plan on or after January 29, 2026. Outstanding grants under the Prior Plan shall continue in effect according to their terms, consistent with the applicable terms of the Prior Plan.

 

Section 1. Definitions

 

The following terms shall have the meanings set forth below for purposes of the Plan:

 

(a) “Board” shall mean the Board of Directors of the Company.

 

(b) “Cause” shall mean, unless otherwise set forth in the Grant Instrument, a finding by the Committee that the Participant (i) has breached the Participant’s employment or service contract with the Company or a subsidiary, (ii) has engaged in disloyalty to the Company or a subsidiary, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty, (iii) has disclosed trade secrets or confidential information of the Company or a subsidiary to persons not entitled to receive such information, (iv) has breached any written non-competition, non-solicitation, invention assignment or confidentiality agreement between the Participant and the Company or a subsidiary or (v) has engaged in such other behavior detrimental to the interests of the Company or a subsidiary as the Committee determines.

 

(c) “CEO” shall mean the Chief Executive Officer of the Company.

 

(d) Unless otherwise set forth in a Grant Instrument, a “Change of Control” shall be deemed to have occurred if:

 

(i) Any “person” (as such term is used in sections 13(d) and 14(d) of the Exchange Act) becomes a “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of a transaction in which the Company becomes a direct or indirect subsidiary of another Person and in which the stockholders of the Company, immediately prior to the transaction, will beneficially own, immediately after the transaction, shares of such other Person representing more than 50% of the voting power of the then outstanding securities of such other Person.

 

 
A-1

Table of Contents

 

(ii) The consummation of (A) a merger or consolidation of the Company with another Person where, immediately after the merger or consolidation, the stockholders of the Company, immediately prior to the merger or consolidation, will not beneficially own, in substantially the same proportion as ownership immediately prior to the merger or consolidation, shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving Person would be entitled in the election of directors, or where the members of the Board, immediately prior to the merger or consolidation, will not, immediately after the merger or consolidation, constitute a majority of the board of directors of the surviving Person or (B) a sale or other disposition of all or substantially all of the assets of the Company.

 

(iii) A change in the composition of the Board over a period of 12 consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections, or threatened election contests, for Board membership, to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least a majority of the Board members described in clause (A) who were still in office at the time the Board approved such election or nomination.

 

(iv) The consummation of a complete dissolution or liquidation of the Company.

 

The Committee may modify the definition of Change of Control for a particular Grant as the Committee deems appropriate to comply with section 409A of the Code or otherwise. Notwithstanding the foregoing, if a Grant constitutes deferred compensation subject to section 409A of the Code and the Grant provides for payment upon a Change of Control, then, for purposes of such payment provisions, no Change of Control shall be deemed to have occurred upon an event described in items (i) – (iv) above unless the event would also constitute a change in ownership or effective control of, or a change in the ownership of a substantial portion of the assets of, the Company under section 409A of the Code.

 

(e) “Code” shall mean the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.

 

(f) “Committee” shall mean the Compensation Committee of the Board or another committee appointed by the Board to administer the Plan. The Committee shall consist of directors who are “non-employee directors” as defined under Rule 16b-3 promulgated under the Exchange Act and “independent directors,” as determined in accordance with the independence standards established by the stock exchange on which the Company Stock is at the time primarily traded.

 

 
A-2

Table of Contents

 

(g) “Company” shall mean TOMI Environmental Solutions, Inc., a Florida corporation, and any successor to all or substantially all of the assets or voting stock of TOMI Environmental Solutions, Inc.

 

(h) “Company Stock” shall mean common stock of the Company, and such other securities as may be substituted for Company Stock pursuant to Section 4(e).

 

(i) “Disability” or “Disabled” shall mean, unless otherwise set forth in the Grant Instrument, a Participant becoming disabled within the meaning of the Company’s or a subsidiary’s long‑term disability plan applicable to the Participant, or, if there is no such plan, the inability of the Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that is expected to result in death or has lasted or can be expected to last for a continuous period of twelve (12) months or more.

 

(j) “Dividend Equivalent” shall mean an amount determined by multiplying the number of shares of Company Stock subject to a Stock Unit or Other Stock-Based Award by the per-share cash dividend paid by the Company on its outstanding Company Stock, or the per-share Fair Market Value of any dividend paid on its outstanding Company Stock in consideration other than cash. If interest is credited on accumulated divided equivalents, the term “Dividend Equivalent” shall include the accrued interest.

 

(k) “Effective Date” shall mean the date of the Annual Meeting of Stockholders to be held on December 18, 2026 or such other date upon which the Company’s stockholders approve the Plan.

 

(l) “Employee” shall mean an employee of the Company or a subsidiary (including an officer or director who is also an employee), but excluding any person who is classified by the Company or a subsidiary as a “contractor” or “consultant,” no matter how characterized by the Internal Revenue Service, other governmental agency or a court. Any change of characterization of an individual by the Internal Revenue Service or any court or government agency shall have no effect upon the classification of an individual as an Employee for purposes of this Plan, unless the Committee determines otherwise.

 

(m) “Exchange Act” shall mean the Securities Exchange Act of 1934, as amended.

 

(n) “Exercise Price” shall mean the per share price at which shares of Company Stock may be purchased under an Option, as designated by the Committee.

 

(o) “Fair Market Value” shall mean:

 

(i) If the Company Stock is publicly traded, the Fair Market Value per share shall be determined as follows: (A) if the principal trading market for the Company Stock is a national securities exchange, the closing sales price during regular trading hours on the relevant date or, if there were no trades on that date, the latest preceding date upon which a sale was reported, or (B) if the Company Stock is not principally traded on any such exchange, the last reported sale price of a share of Company Stock during regular trading hours on the relevant date, as reported by the OTC Bulletin Board.

 

 
A-3

Table of Contents

 

(ii) If the Company Stock is not publicly traded or, if publicly traded, is not subject to reported transactions as set forth above, the Fair Market Value per share shall be determined by the Committee through any reasonable valuation method authorized under the Code.

 

(p) “Grant” shall mean an Option, SAR, Stock Award, Stock Unit or Other Stock-Based Award granted under the Plan.

 

(q) “Grant Instrument” shall mean the written agreement that sets forth the terms and conditions of a Grant, including all amendments thereto.

 

(r) “Incentive Stock Option” shall mean an Option that satisfies the requirements of an incentive stock option under section 422 of the Code.

 

(s) “Key Advisor” shall mean a consultant or advisor of the Company or a subsidiary.

 

(t) “Non-Employee Director” shall mean a member of the Board, or a member of the board of directors of a subsidiary of the Company, who is not an Employee.

 

(u) “Nonqualified Stock Option” shall mean an Option that is not an Incentive Stock Option.

 

(v) “Option” shall mean an option to purchase shares of Company Stock, as described in Section 6.

 

(w) “Other Stock-Based Award” shall mean any Grant based on, measured by or payable in Company Stock (other than an Option, Stock Unit, Stock Award, or SAR), as described in Section 10.

 

(x) “Participant” shall mean an Employee, Key Advisor or Non-Employee Director that is granted a Grant under the Plan.

 

(y) “Performance Goals” shall mean any objective or subjective goals the Committee establishes with respect to a Grant. Performance Goals may include, but are not limited to, the following performance criteria upon which the vesting of one or more Grants under the Plan may be based: cash flow; free cash flow; adjusted cash flow from operations; adjusted cash flow per share; earnings (including gross margin, earnings before interest and taxes, earnings before taxes, earnings before interest, taxes, depreciation, amortization and charges for stock-based compensation, earnings before interest, taxes, depreciation and amortization, adjusted earnings before interest, taxes, depreciation and amortization and net earnings); earnings per share; growth in earnings or earnings per share; book value growth; stock price; return on equity or average stockholder equity; total stockholder return or growth in total stockholder return either directly or in relation to a comparative group; return on capital; return on assets or net assets; revenue, growth in revenue or return on sales; sales; expense reduction or expense control; expense to revenue ratio; equity ratios; debt level; cost reduction targets; income, net income or adjusted net income; operating income, net operating income, adjusted operating income or net operating income after tax; operating profit or net operating profit; operating margin; gross profit margin; return on operating revenue or return on operating profit; return on investment; regulatory filings; regulatory approvals, litigation and regulatory resolution goals; other operational, regulatory or departmental objectives; budget comparisons; growth in stockholder value relative to established indexes, or another peer group or peer group index; development and implementation of strategic plans and/or organizational restructuring goals; development and implementation of risk and crisis management programs; improvement in workforce diversity; compliance requirements and compliance relief; safety goals; productivity goals; workforce management and succession planning goals; economic value added (including typical adjustments consistently applied from generally accepted accounting principles required to determine economic value added performance measures); measures of customer satisfaction, employee satisfaction or staff development; development or marketing collaborations, formations of joint ventures or partnerships or the completion of other similar transactions intended to enhance the Company’s revenue or profitability or enhance its customer base; merger and acquisitions; and other similar criteria as determined by the Committee. Performance goals applicable to a Grant shall be determined by the Committee, and may be established on an absolute or relative basis and may be established on a corporate-wide basis or with respect to one or more business units, divisions, subsidiaries or business segments. Relative performance may be measured against a group of peer companies, a financial market index or other objective and quantifiable indices.

 

 
A-4

Table of Contents

 

(z) “Person” shall mean any natural person, corporation, limited liability company, partnership, trust, joint stock company, business trust, unincorporated association, joint venture, governmental authority or other legal entity of any nature whatsoever.

 

(aa) “Prior Plan” shall mean the TOMI Environmental Solutions, Inc. Amended and Restated 2016 Equity Incentive Plan.

 

(bb) “Restriction Period” shall have the meaning given that term in Section 7(a).

 

(cc) “SAR” shall mean a stock appreciation right, as described in Section 9.

 

(dd) “Service” shall mean, unless otherwise set forth in a Grant Instrument, employment or service as an Employee, Key Advisor or member of the Board (so that, for purposes of exercising Options and SARs and satisfying conditions with respect to Stock Awards, Stock Units, and Other Stock-Based Awards, a Participant shall not be considered to have terminated Service until the Participant ceases to be an Employee, Key Advisor and member of the Board), unless the Committee determines otherwise. If a Participant’s relationship is with a subsidiary of the Company and that entity ceases to be a subsidiary of the Company, the Participant will be deemed to cease Service when the entity ceases to be a subsidiary of the Company, unless the Participant transfers employment or service to the Company or a subsidiary. If a Participant has military, sick leave or other bona fide leave, the Participant will not be deemed to cease Service solely as a result of such leave; provided that such leave does not exceed the longer of 90 days or the period during which the absent Participant’s reemployment rights, if any, are guaranteed by statute or contract. To the extent consistent with applicable law, the Committee may provide that Grants continue to vest for all or a portion of the period of such leave, or that vesting shall be tolled during such leave and only recommence upon the Participant’s return from such leave.

 

(ee) “Stock Award” shall mean an award of Company Stock, as described in Section 7.

 

(ff) “Stock Unit” shall mean an award of a phantom unit representing a share of Company Stock, as described in Section 8.

 

(gg) “Substitute Awards” shall have the meaning given that term in Section 4(c).

 

Section 2. Administration

 

(a) Committee. The Plan shall be administered and interpreted by the Committee; provided, however, that any Grants to members of the Board must be authorized by a majority of the Board. The Committee may delegate authority to one or more subcommittees, as it deems appropriate. Subject to compliance with applicable law and the applicable stock exchange rules, the Board, in its discretion, may perform any action of the Committee hereunder. To the extent that the Board, a subcommittee or the CEO, as described below administers the Plan, references in the Plan to the “Committee” shall be deemed to refer to the Board or such subcommittee or the CEO.

 

(b) Delegation to CEO. Subject to compliance with applicable law and applicable stock exchange requirements, the Committee may delegate all or part of its authority and power to the CEO, as it deems appropriate, with respect to Grants to Employees or Key Advisors who are not executive officers or directors under section 16 of the Exchange Act.

 

 
A-5

Table of Contents

 

(c) Committee Authority. The Committee shall have the sole authority to (i) determine the individuals to whom Grants shall be made under the Plan, (ii) determine the type, size, terms and conditions of the Grants to be made to each such individual, (iii) determine the time when the Grants will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of exercisability, (iv) amend the terms of any previously issued Grant, subject to the provisions of Section 17 below, (v) determine and adopt terms, guidelines, and provisions, not inconsistent with the Plan and applicable law, that apply to individuals residing outside of the United States who receive Grants under the Plan, (vi) deal with any other matters arising under the Plan, and (vii) in the event of a Change of Control, take any action authorized by Section 12 hereof.

 

(d) Committee Determinations. The Committee shall have full power and express discretionary authority to administer and interpret the Plan, to make factual determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. The Committee’s interpretations of the Plan and all determinations made by the Committee pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in the Plan or in any Grants granted hereunder. All powers of the Committee shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary, and in keeping with the objectives of the Plan and need not be uniform as to similarly situated individuals.

 

(e) Indemnification. No member of the Committee or the Board, and no employee of the Company shall be liable for any act or failure to act with respect to the Plan, except in circumstances involving such person’s bad faith or willful misconduct, or for any act or failure to act hereunder by any other member of the Committee or employee or by any agent to whom duties in connection with the administration of this Plan have been delegated. The Company shall indemnify members of the Committee and the Board and any agent of the Committee or the Board who is an employee of the Company or a subsidiary against any and all liabilities or expenses to which they may be subjected by reason of any act or failure to act with respect to their duties on behalf of the Plan, except in circumstances involving such person’s bad faith or willful misconduct.

 

Section 3. Grants

 

Grants under the Plan may consist of Options as described in Section 6, Stock Awards as described in Section 7, Stock Units as described in Section 8, SARs as described in Section 9, and Other Stock-Based Awards as described in Section 10. All Grants shall be subject to the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the Committee deems appropriate and as are specified in writing by the Committee to the individual in the Grant Instrument. All Grants shall be made conditional upon the Participant’s acknowledgement, in writing or by acceptance of the Grant, that all decisions and determinations of the Committee shall be final and binding on the Participant, the Participant’s beneficiaries and any other person having or claiming an interest under such Grant. Grants under a particular Section of the Plan need not be uniform as among the Participants.

 

Section 4. Shares Subject to the Plan

 

(a) Shares Authorized. Subject to adjustment as described below in Sections 4(b) and 4(e) below, the aggregate number of shares of Company Stock that may be issued or transferred under the Plan shall be 3,500,000 shares of Company Stock. In addition, shares of the Company Stock underlying any outstanding award granted under the Prior Plan that, following the Effective Date, expires, or is terminated, surrendered or forfeited for any reason without issuance of such shares shall be available for the award of new Grants under this Plan. Subject to adjustment as described below in Sections 4(b) and 4(e) below, the aggregate number of shares of Company Stock that may be issued or transferred under the Plan pursuant to Incentive Stock Options shall not exceed 3,500,000 shares of Company Stock.

 

 
A-6

Table of Contents

 

(b) Source of Shares; Share Counting. Shares issued or transferred under the Plan may be authorized but unissued shares of Company Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of the Plan. If and to the extent Options or SARs granted under the Plan expire or are canceled, forfeited, exchanged or surrendered without having been exercised, or if any Stock Awards, Stock Units or Other Stock-Based Awards are forfeited, terminated or otherwise not paid in full, the shares subject to such Grants shall again be available for purposes of the Plan. If shares of Company Stock otherwise issuable under the Plan are surrendered in payment of the Exercise Price of an Option, then the number of shares of Company Stock available for issuance under the Plan shall be reduced only by the net number of shares actually issued by the Company upon such exercise and not by the gross number of shares as to which such Option is exercised. Upon the exercise of any SAR under the Plan, the number of shares of Company Stock available for issuance under the Plan shall be reduced by only by the net number of shares actually issued by the Company upon such exercise. If shares of Company Stock otherwise issuable under the Plan are withheld by the Company in satisfaction of the withholding taxes incurred in connection with the issuance, vesting or exercise of any Grant or the issuance of Company Stock thereunder, then the number of shares of Company Stock available for issuance under the Plan shall be reduced by the net number of shares issued, vested or exercised under such Grant, calculated in each instance after payment of such share withholding. To the extent any Grants are paid in cash, and not in shares of Company Stock, any shares previously subject to such Grants shall again be available for issuance or transfer under the Plan. For the avoidance of doubt, if shares are repurchased by the Company on the open market with the proceeds of the Exercise Price of Options, such shares may not again be made available for issuance under the Plan.

 

(c) Substitute Awards. Shares issued or transferred under Grants made pursuant to an assumption, substitution or exchange for previously granted awards of a company acquired by the Company in a transaction (“Substitute Awards”) shall not reduce the number of shares of Company Stock available under the Plan and available shares under a stockholder approved plan of an acquired company (as appropriately adjusted to reflect the transaction) may be used for Grants under the Plan and shall not reduce the Plan’s share reserve (subject to applicable stock exchange listing and Code requirements).

 

(d) Adjustments. If there is any change in the number or kind of shares of Company Stock outstanding by reason of (i) a stock dividend, spinoff, recapitalization, stock split, reverse stock split or combination or exchange of shares, (ii) a merger, reorganization or consolidation, (iii) a reclassification or change in par value, or (iv) any other extraordinary or unusual event affecting the outstanding Company Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution,

 

(A) the maximum number and kind of shares of Company Stock available for issuance under the Plan, (B) the maximum number and/or class of securities that may be issued pursuant to Incentive Stock Options granted under the Plan, (C) the maximum value of Grants that a Non-Employee Director may receive in any year, (D) the number and kind of shares and the exercise, purchase or base price per share in effect under each outstanding Grant, and (E) such other terms and conditions for outstanding Grants as the Committee deems appropriate, shall be equitably adjusted by the Committee to reflect any increase or decrease in the number of, or change in the kind or value of, the issued shares of Company Stock to preclude, to the extent practicable, the enlargement or dilution of rights and benefits under the Plan and such outstanding Grants; provided, however, that any fractional shares resulting from such adjustment shall be eliminated. In addition, in the event of a Change of Control, the provisions of Section 12 of the Plan shall apply. Any adjustments to outstanding Grants shall be consistent with section 409A or 424 of the Code, to the extent applicable. Subject to Section 17(b), the adjustments of Grants under this Section 4(e) shall include adjustment of shares, Exercise Price of Stock Options, base amount of SARs, Performance Goals or other terms and conditions, as the Committee deems appropriate. The Committee shall have the sole discretion and authority to determine what appropriate adjustments shall be made and any adjustments determined by the Committee shall be final, binding and conclusive.

 

 
A-7

Table of Contents

 

Section 5. Eligibility for Participation

 

(a) Eligible Persons. All Employees and Non-Employee Directors shall be eligible to participate in the Plan. Key Advisors shall be eligible to participate in the Plan if the Key Advisors render bona fide services to the Company or a subsidiary, the services are not in connection with the offer and sale of securities in a capital-raising transaction and the Key Advisors do not directly or indirectly promote or maintain a market for the Company’s securities.

 

(b) Selection of Participants. The Committee shall select the Employees, Non-Employee Directors and Key Advisors to receive Grants and shall determine the number of shares of Company Stock subject to a particular Grant in such manner as the Committee determines.

 

Section 6. Options

 

The Committee may grant Options to an Employee, Non-Employee Director or Key Advisor upon such terms as the Committee deems appropriate. The following provisions are applicable to Options:

 

(a) Number of Shares. The Committee shall determine the number of shares of Company Stock that will be subject to each Grant of an Option to Employees, Non-Employee Directors and Key Advisors.

 

(b) Type of Option and Exercise Price.

 

(i) The Committee may grant Incentive Stock Options or Nonqualified Stock Options or any combination of the two, all in accordance with the terms and conditions set forth herein. Incentive Stock Options may be granted only to employees of the Company or its parent or subsidiary corporations, as defined in section 424 of the Code. Nonqualified Stock Options may be granted to Employees, Non‑Employee Directors and Key Advisors.

 

(ii) The Exercise Price of Company Stock subject to an Option shall be determined by the Committee and shall be equal to or greater than the Fair Market Value of a share of Company Stock on the date the Option is granted. However, an Incentive Stock Option may not be granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary corporation of the Company, as defined in section 424 of the Code, unless the Exercise Price per share is not less than 110% of the Fair Market Value of a share of Company Stock on the date of grant.

 

(c) Option Term. The Committee shall determine the term of each Option. The term of any Option shall not exceed ten years from the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of grant, owns stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary corporation of the Company, as defined in section 424 of the Code, may not have a term that exceeds five years from the date of grant. Notwithstanding the foregoing, in the event that on the last business day of the term of an Option (other than an Incentive Stock Option), the exercise of the Option is prohibited by applicable law, including a prohibition on purchases or sales of Company Stock under the Company’s insider trading policy, the term of the Option shall be extended for a period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise.

 

 
A-8

Table of Contents

 

(d) Exercisability of Options. Options shall become exercisable in accordance with such terms and conditions, consistent with the Plan, as may be determined by the Committee and specified in the Grant Instrument. The Committee may accelerate the exercisability of any or all outstanding Options at any time for any reason.

 

(e) Grants to Non-Exempt Employees. Notwithstanding the foregoing, Options granted to persons who are non‑exempt employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such Options may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations).

 

(f) Termination of Service. Except as provided in the Grant Instrument, an Option may only be exercised while the Participant is in Service. The Committee shall determine in the Grant Instrument under what circumstances and during what time periods a Participant may exercise an Option after termination of Service.

 

(g) Exercise of Options. A Participant may exercise an Option that has become exercisable, in whole or in part, by delivering a notice of exercise to the Company. The Participant shall pay the Exercise Price for an Option as specified by the Committee (i) in cash, (ii) unless the Committee determines otherwise, by delivering shares of Company Stock owned by the Participant and having a Fair Market Value on the date of exercise at least equal to the Exercise Price or by attestation (in accordance with procedures prescribed by the Company) to ownership of shares of Company Stock having a Fair Market Value on the date of exercise at least equal to the Exercise Price, (iii) unless the Committee determines otherwise, by payment through a broker in accordance with procedures permitted by Regulation T of the Federal Reserve Board, (iv) if permitted by the Committee, by withholding shares of Company Stock subject to the exercisable Option, which have a Fair Market Value on the date of exercise equal to the Exercise Price, or (v) by such other method as the Committee may approve. Shares of Company Stock used to exercise an Option shall have been held by the Participant for the requisite period of time necessary to avoid adverse accounting consequences to the Company with respect to the Option. Payment for the shares to be issued or transferred pursuant to the Option, and any required withholding taxes, must be received by the Company by the time specified by the Committee depending on the type of payment being made, but in all cases prior to the issuance or transfer of such shares.

 

(h) Limits on Incentive Stock Options. Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the Company Stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar year, under the Plan or any other stock option plan of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess, shall be treated as a Nonqualified Stock Option.

 

Section 7. Stock Awards

 

The Committee may issue or transfer shares of Company Stock to an Employee, Non‑Employee Director or Key Advisor under a Stock Award, upon such terms as the Committee deems appropriate. The following provisions are applicable to Stock Awards:

 

(a) General Requirements. Shares of Company Stock issued or transferred pursuant to Stock Awards may be issued or transferred for consideration or for no consideration, and subject to restrictions or no restrictions, as determined by the Committee. The Committee may, but shall not be required to, establish conditions under which restrictions on Stock Awards shall lapse over a period of time or according to such other criteria as the Committee deems appropriate, including, without limitation, restrictions based on the achievement of specific Performance Goals. The period of time during which the Stock Awards will remain subject to restrictions will be designated in the Grant Instrument as the “Restriction Period.”

 

 
A-9

Table of Contents

 

(b) Number of Shares. The Committee shall determine the number of shares of Company Stock to be issued or transferred pursuant to a Stock Award and the restrictions applicable to such shares.

 

(c) Requirement of Employment or Service. If the Participant’s Service ceases for any reason during a period designated in the Grant Instrument as the Restriction Period, or if other specified conditions are not met, the Stock Award shall terminate as to all shares covered by the Grant as to which the restrictions have not lapsed, and those shares of Company Stock must be immediately returned to the Company. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.

 

(d) Restrictions on Transfer and Legend on Stock Certificate. During the Restriction Period, a Participant may not sell, assign, transfer, pledge or otherwise dispose of the shares of a Stock Award except under Section 15 below. Unless otherwise determined by the Committee, the Company will retain possession of certificates for shares of Stock Awards until all restrictions on such shares have lapsed. Each certificate for a Stock Award, unless held by the Company, shall contain a legend giving appropriate notice of the restrictions in the Grant. The Participant shall be entitled to have the legend removed from the stock certificate covering the shares subject to restrictions when all restrictions on such shares have lapsed. The Committee may determine that the Company will not issue certificates for Stock Awards until all restrictions on such shares have lapsed.

 

(e) Right to Vote and to Receive Dividends. Unless the Committee determines otherwise, during the Restriction Period, the Participant shall have the right to vote shares of Stock Awards and to receive any dividends or other distributions paid on such shares, subject to any restrictions deemed appropriate by the Committee, including, without limitation, the achievement of specific Performance Goals. Dividends with respect to Stock Awards that vest based on performance shall vest if and to the extent that the underlying Stock Award vests, as determined by the Committee.

 

(f) Lapse of Restrictions. All restrictions imposed on Stock Awards shall lapse upon the expiration of the applicable Restriction Period and the satisfaction of all conditions, if any, imposed by the Committee. The Committee may determine, as to any or all Stock Awards, that the restrictions shall lapse without regard to any Restriction Period.

 

Section 8. Stock Units

 

The Committee may grant Stock Units, each of which shall represent one hypothetical share of Company Stock, to an Employee, Non-Employee Director or Key Advisor upon such terms and conditions as the Committee deems appropriate. The following provisions are applicable to Stock Units:

 

(a) Crediting of Units. Each Stock Unit shall represent the right of the Participant to receive a share of Company Stock or an amount of cash based on the value of a share of Company Stock, if and when specified conditions are met. All Stock Units shall be credited to bookkeeping accounts established on the Company’s records for purposes of the Plan.

 

 
A-10

Table of Contents

 

(b) Terms of Stock Units. The Committee may grant Stock Units that vest and are payable if specified Performance Goals or other conditions are met, or under other circumstances. Stock Units may be paid at the end of a specified performance period or other period, or payment may be deferred to a date authorized by the Committee. The Committee may accelerate vesting or payment, as to any or all Stock Units at any time for any reason, provided such acceleration complies with section 409A of the Code. The Committee shall determine the number of Stock Units to be granted and the requirements applicable to such Stock Units.

 

(c) Requirement of Employment or Service. If the Participant’s Service ceases for any reason prior to the vesting of Stock Units, or if other conditions established by the Committee are not met, the Participant’s Stock Units shall be forfeited. The Committee may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.

 

(d) Payment With Respect to Stock Units. Payments with respect to Stock Units shall be made in cash, Company Stock or any combination of the foregoing, as the Committee shall determine.

 

Section 9. Stock Appreciation Rights

 

The Committee may grant SARs to an Employee, Non‑Employee Director or Key Advisor separately or in tandem with any Option. The following provisions are applicable to SARs:

 

(a) General Requirements. The Committee may grant SARs to an Employee, Non‑Employee Director or Key Advisor separately or in tandem with any Option (for all or a portion of the applicable Option). Tandem SARs may be granted either at the time the Option is granted or at any time thereafter while the Option remains outstanding; provided, however, that, in the case of an Incentive Stock Option, SARs may be granted only at the time of the grant of the Incentive Stock Option. The Committee shall establish the base amount of the SAR at the time the SAR is granted. The base amount of each SAR shall be equal to or greater than the Fair Market Value of a share of Company Stock as of the date of grant of the SAR. The term of any SAR shall not exceed ten years from the date of grant. Notwithstanding the foregoing, in the event that on the last business day of the term of a SAR, the exercise of the SAR is prohibited by applicable law, including a prohibition on purchases or sales of Company Stock under the Company’s insider trading policy, the term shall be extended for a period of 30 days following the end of the legal prohibition, unless the Committee determines otherwise.

 

(b) Tandem SARs. In the case of tandem SARs, the number of SARs granted to a Participant that shall be exercisable during a specified period shall not exceed the number of shares of Company Stock that the Participant may purchase upon the exercise of the related Option during such period. Upon the exercise of an Option, the SARs relating to the Company Stock covered by such Option shall terminate. Upon the exercise of SARs, the related Option shall terminate to the extent of an equal number of shares of Company Stock.

 

(c) Exercisability. A SAR shall be exercisable during the period specified by the Committee in the Grant Instrument and shall be subject to such vesting and other restrictions as may be specified in the Grant Instrument. The Committee may accelerate the exercisability of any or all outstanding SARs at any time for any reason. SARs may only be exercised while the Participant is in Service or during the applicable period after termination of Service as specified by the Committee. A tandem SAR shall be exercisable only during the period when the Option to which it is related is also exercisable.

 

 
A-11

Table of Contents

 

(d) Grants to Non‑Exempt Employees. Notwithstanding the foregoing, SARs granted to persons who are non‑exempt employees under the Fair Labor Standards Act of 1938, as amended, may not be exercisable for at least six months after the date of grant (except that such SARs may become exercisable, as determined by the Committee, upon the Participant’s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by applicable regulations).

 

(e) Value of SARs. When a Participant exercises SARs, the Participant shall receive in settlement of such SARs an amount equal to the value of the stock appreciation for the number of SARs exercised. The stock appreciation for a SAR is the amount by which the Fair Market Value of the underlying Company Stock on the date of exercise of the SAR exceeds the base amount of the SAR as described in subsection (a).

 

(f) Form of Payment. The appreciation in a SAR shall be paid in shares of Company Stock, cash or any combination of the foregoing, as the Committee shall determine. For purposes of calculating the number of shares of Company Stock to be received, shares of Company Stock shall be valued at their Fair Market Value on thedate of exercise of the SAR.

 

Section 10. Other Stock-Based Awards

 

The Committee may grant Other Stock-Based Awards, which are awards (other than those described in Sections 6, 7, 8 and 9 of the Plan) that are based on or measured by Company Stock, to any Employee, Non-Employee Director or Key Advisor, on such terms and conditions as the Committee shall determine. Other Stock-Based Awards may be awarded subject to the achievement of Performance Goals or other criteria or other conditions and may be payable in cash, Company Stock or any combination of the foregoing, as the Committee shall determine.

 

Section 11. Dividend Equivalents

 

The Committee may grant Dividend Equivalents in connection with Stock Units or Other Stock-Based Awards. Dividend Equivalents may be paid currently or accrued as contingent cash obligations and may be payable in cash or shares of Company Stock, and upon such terms and conditions as the Committee shall determine. Dividend Equivalents with respect to Stock Units or Other Stock-Based Awards that vest based on performance shall vest and be paid only if and to the extent the underlying Stock Units or Other Stock-Based Awards vest and are paid, as determined by the Committee. For the avoidance of doubt, no dividends or Dividend Equivalents will be granted in connection with Options or SARs.

 

Section 12. Consequences of a Change of Control

 

(a) Assumption of Outstanding Grants. Upon a Change of Control where the Company is not the surviving corporation (or survives only as a subsidiary of another corporation), unless the Committee determines otherwise, all outstanding Grants that are not exercised or paid at the time of the Change of Control shall be assumed by, or replaced with grants (with respect to cash, securities, or a combination thereof) that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation). After a Change of Control, references to the “Company” as they relate to employment matters shall include the successor employer in the transaction, subject to applicable law.

 

 
A-12

Table of Contents

 

(b) Other Alternatives. In the event of a Change of Control, if any outstanding Grants are not assumed by, or replaced with grants that have comparable terms by, the surviving corporation (or a parent or subsidiary of the surviving corporation), the Committee may (but is not obligated to) make adjustments to the terms and conditions of outstanding Grants, including, without limitation, taking any of the following actions (or combination thereof) with respect to any or all outstanding Grants, without the consent of any Participant: (i) the Committee may determine that outstanding Stock Options and SARs shall automatically accelerate and become fully exercisable and the restrictions and conditions on outstanding Stock Awards, Stock Units and Dividend Equivalents shall immediately lapse; (ii) the Committee may determine that Participants shall receive a payment in settlement of outstanding Stock Units, Other Stock-Based Awards or Dividend Equivalents, in such amount and form as may be determined by the Committee; (iii) the Committee may require that Participants surrender their outstanding Stock Options and SARs in exchange for a payment by the Company, in cash or Company Stock as determined by the Committee, in an amount equal to the amount, if any, by which the then Fair Market Value of the shares of Company Stock subject to the Participant’s unexercised Stock Options and SARs exceeds the Stock Option Exercise Price or SAR base amount; and (iv) after giving Participants an opportunity to exercise all of their outstanding Stock Options and SARs, the Committee may terminate any or all unexercised Stock Options and SARs at such time as the Committee deems appropriate. Such surrender, termination or payment shall take place as of the date of the Change of Control or such other date as the Committee may specify. Without limiting the foregoing, if the per share Fair Market Value of the Company Stock does not exceed the per share Stock Option Exercise Price or SAR base amount, as applicable, the Company shall not be required to make any payment to the Participant upon surrender of the Stock Option or SAR. The Committee shall have the authority to provide that any escrow, holdback, earn-out or similar provisions in the definitive agreement effecting the Change of Control shall apply to any cash payment made pursuant to this Section 12 to the same extent and in the same manner as such provisions apply to a holder of a share of Company Stock.

 

Section 13. Deferrals

 

The Committee may permit or require a Participant to defer receipt of the payment of cash or the delivery of shares that would otherwise be due to such Participant in connection with any Grant. If any such deferral election is permitted or required, the Committee shall establish rules and procedures for such deferrals and may provide for interest or other earnings to be paid on such deferrals. The rules and procedures for any such deferrals shall be consistent with applicable requirements of section 409A of the Code.

 

Section 14. Withholding of Taxes

 

(a) Required Withholding. All Grants under the Plan shall be subject to applicable United States federal (including FICA), state and local, foreign country or other tax withholding requirements. The Company or any of its subsidiaries may require that the Participant or other person receiving Grants or exercising Grants pay to the Company or any of its subsidiaries an amount sufficient to satisfy such tax withholding requirements with respect to such Grants, or the Company or any of its subsidiaries may deduct from other wages and compensation paid by the Company or any of its subsidiaries the amount of any withholding taxes due with respect to such Grants.

 

(b) Share Withholding. The Committee may permit or require the Company’s or any of its subsidiary’s tax withholding obligation with respect to Grants paid in Company Stock to be satisfied by having shares withheld up to an amount that does not exceed the Participant’s applicable withholding tax rate for United States federal (including FICA), state and local, foreign country or other tax liabilities. The Committee may, in its discretion, and subject to such rules as the Committee may adopt, allow Participants to elect to have such share withholding applied to all or a portion of the tax withholding obligation arising in connection with any particular Grant. Unless the Committee determines otherwise, share withholding for taxes shall not exceed the Participant’s minimum applicable tax withholding amount.

 

 
A-13

Table of Contents

 

Section 15. Transferability of Grants

 

(a) Nontransferability of Grants. Except as described in subsection (b) below, only the Participant may exercise rights under a Grant during the Participant’s lifetime. A Participant may not transfer those rights except (i) by will or by the laws of descent and distribution or (ii) with respect to Grants other than Incentive Stock Options, pursuant to a domestic relations order. When a Participant dies, the personal representative or other person entitled to succeed to the rights of the Participant may exercise such rights. Any such successor must furnish proof satisfactory to the Company of the successor’s right to receive the Grant under the Participant’s will or under the applicable laws of descent and distribution.

 

(b) Transfer of Nonqualified Stock Options and Stock Awards. Notwithstanding the foregoing, the Committee may provide, in a Grant Instrument or at such other time after the grant of an award, that a Participant may transfer Nonqualified Stock Options or Stock Awards to family members, or one or more trusts or other entities for the benefit of or owned by family members, consistent with the applicable securities laws, according to such terms as the Committee may determine; provided that the Participant receives no consideration for the transfer of an Option or Stock Award and the transferred Option or Stock Award shall continue to be subject to the same terms and conditions as were applicable to the Option or Stock Award immediately before the transfer.

 

Section 16. Requirements for Issuance or Transfer of Shares

 

No Company Stock shall be issued or transferred in connection with any Grant hereunder unless and until all legal requirements applicable to the issuance or transfer of such Company Stock have been complied with to the satisfaction of the Committee. The Committee shall have the right to condition any Grant on the Participant’s undertaking in writing to comply with such restrictions on the Participant’s subsequent disposition of the shares of Company Stock as the Committee shall deem necessary or advisable, and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing shares of Company Stock issued or transferred under the Plan may be subject to such stop-transfer orders and other restrictions as the Committee deems appropriate to comply with applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon.

 

Section 17. Amendment and Termination of the Plan

 

(a) Amendment. The Board may amend or terminate the Plan at any time; provided, however, that the Board shall not amend the Plan without stockholder approval if such approval is required in order to comply with the Code or other applicable law, or to comply with applicable stock exchange requirements.

 

(b) No Repricing of Options or SARs. Except pursuant to Section 4(e), the Company may not, without obtaining stockholder approval, (i) amend the terms of outstanding Stock Options or SARs to reduce the Exercise Price of such outstanding Stock Options or base price of such SARs, (ii) cancel outstanding Stock Options or SARs in exchange for Stock Options or SARs with an Exercise Price or base price, as applicable, that is less than the Exercise Price or base price of the original Stock Options or SARs or (iii) cancel outstanding Stock Options or SARs with an Exercise Price or base price, as applicable, above the current stock price in exchange for cash or other securities.

 

(c) Termination of Plan. The Plan shall terminate on the day immediately preceding the tenth anniversary of its Effective Date, unless the Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders.

 

 
A-14

Table of Contents

 

(d) Termination and Amendment of Outstanding Grants. A termination or amendment of the Plan that occurs after a Grant is made shall not materially impair the rights of a Participant with respect to such Grant unless the Participant consents or unless the Committee acts under Section 18(f) below. The termination of the Plan shall not impair the power and authority of the Committee with respect to an outstanding Grant. Whether or not the Plan has terminated, an outstanding Grant may be terminated or amended under Section 18(f) below or may be amended by agreement of the Company and the Participant consistent with the Plan, provided that, the Participant’s consent is not required if any termination or amendment to the Participant’s outstanding Grant does not materially impair the rights or materially increase the obligations of the Participant.

 

Section 18. Miscellaneous

 

(a) Grants in Connection with Corporate Transactions and Otherwise. Nothing contained in the Plan shall be construed to (i) limit the right of the Committee to make Grants under the Plan in connection with the acquisition, by purchase, lease, merger, consolidation or otherwise, of the business or assets of any corporation, firm or association, including Grants to employees thereof who become Employees, or (ii) limit the right of the Company to grant stock options or make other awards outside of the Plan. The Committee may make a Grant to an employee of another corporation who becomes an Employee by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation involving the Company, in substitution for a stock option or stock award grant made by such corporation. Notwithstanding anything in the Plan to the contrary, the Committee may establish such terms and conditions of the new Grants as it deems appropriate, including setting the Exercise Price of Options or the base price of SARs at a price necessary to retain for the Participant the same economic value as the prior options or rights.

 

(b) Governing Document. The Plan shall be the controlling document. No other statements, representations, explanatory materials or examples, oral or written, may amend the Plan in any manner. The Plan shall be binding upon and enforceable against the Company and its successors and assigns.

 

(c) Funding of the Plan. The Plan shall be unfunded. The Company shall not be required to establish any special or separate fund or to make any other segregation of assets to assure the payment of any Grants under the Plan.

 

(d) Rights of Participants. Nothing in the Plan shall entitle any Employee, Non‑Employee Director, Key Advisor or other person to any claim or right to receive a Grant under the Plan. Neither the Plan nor any action taken hereunder shall be construed as giving any individual any rights to be retained by or in the employ of the Company or any of its subsidiaries or any other employment rights.

 

(e) No Fractional Shares. No fractional shares of Company Stock shall be issued or delivered pursuant to the Plan or any Grant. Except as otherwise provided under the Plan, the Committee shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such fractional shares or any rights thereto shall be forfeited or otherwise eliminated.

 

(f) Compliance with Law.

 

(i) The Plan, the exercise of Options and SARs and the obligations of the Company to issue or transfer shares of Company Stock under Grants shall be subject to all applicable laws and regulations, and to approvals by any governmental or regulatory agency as may be required. With respect to persons subject to section 16 of the Exchange Act, it is the intent of the Company that the Plan and all transactions under the Plan comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act. In addition, it is the intent of the Company that Incentive Stock Options comply with the applicable provisions of section 422 of the Code, and that, to the extent applicable, Grants comply with the requirements of section 409A of the Code. To the extent that any legal requirement of section 16 of the Exchange Act or section 422 or 409A of the Code as set forth in the Plan ceases to be required under section 16 of the Exchange Act or section 422 or 409A of the Code, that Plan provision shall cease to apply. The Committee may revoke any Grant if it is contrary to law or modify a Grant to bring it into compliance with any valid and mandatory government regulation. The Committee may also adopt rules regarding the withholding of taxes on payments to Participants. The Committee may, in its sole discretion, agree to limit its authority under this Section.

 

 
A-15

Table of Contents

 

(ii) The Plan is intended to comply with the requirements of section 409A of the Code, to the extent applicable. Each Grant shall be construed and administered such that the Grant either (A) qualifies for an exemption from the requirements of section 409A of the Code or (B) satisfies the requirements of section 409A of the Code. If a Grant is subject to section 409A of the Code, (I) distributions shall only be made in a manner and upon an event permitted under section 409A of the Code, (II) payments to be made upon a termination of employment or service shall only be made upon a “separation from service” under section 409A of the Code, (III) unless the Grant specifies otherwise, each installment payment shall be treated as a separate payment for purposes of section 409A of the Code, and (IV) in no event shall a Participant, directly or indirectly, designate the calendar year in which a distribution is made except in accordance with section 409A of the Code.

 

(iii) Any Grant that is subject to section 409A of the Code and that is to be distributed to a Key Employee (as defined below) upon separation from service shall be administered so that any distribution with respect to such Grant shall be postponed for six months following the date of the Participant’s separation from service, if required by section 409A of the Code. If a distribution is delayed pursuant to section 409A of the Code, the distribution shall be paid within 15 days after the end of the six-month period. If the Participant dies during such six-month period, any postponed amounts shall be paid within 90 days of the Participant’s death. The determination of Key Employees, including the number and identity of persons considered Key Employees and the identification date, shall be made by the Committee or its delegate each year in accordance with section 416(i) of the Code and the “specified employee” requirements of section 409A of the Code.

 

(iv) Notwithstanding anything in the Plan or any Grant Instrument to the contrary, each Participant shall be solely responsible for the tax consequences of Grants under the Plan, and in no event shall the Company or any subsidiary or affiliate of the Company have any responsibility or liability if a Grant does not meet any applicable requirements of section 409A of the Code. Although the Company intends to administer the Plan to prevent taxation under section 409A of the Code, the Company does not represent or warrant that the Plan or any Grant complies with any provision of federal, state, local or other tax law.

 

(g) Grants in Foreign Countries; Establishment of Subplans. The Committee has the authority to award Grants to Participants who are foreign nationals or employed outside the United States on any different terms and conditions than those specified in the Plan that the Committee, in its discretion, believes to be necessary or desirable to accommodate differences in applicable law, tax policy, or custom, while furthering the purposes of the Plan. The Board may from time to time establish one or more sub-plans under the Plan for purposes of satisfying applicable blue sky, securities or tax laws of various jurisdictions. The Board shall establish such sub-plans by adopting supplements to the Plan setting forth (i) such limitations on the Committee’s discretion under the Plan as the Board deems necessary or desirable and (ii) such additional terms and conditions not otherwise inconsistent with the Plan as the Board shall deem necessary or desirable. All supplements adopted by the Board shall be deemed to be part of the Plan, but each supplement shall apply only to Participants within the affected jurisdiction and the Company and its subsidiaries shall not be required to provide copies of any supplement to Participants in any jurisdiction that is not affected. Notwithstanding the foregoing, the Committee may not approve any sub-plan inconsistent with the terms or share limits in the Plan or which would otherwise cause the Plan to cease to satisfy any conditions under Rule 16b-3 under the Exchange Act.

 

(h) Clawback Rights. Subject to the requirements of applicable law, the Committee may provide in any Grant Instrument that, if a Participant breaches any restrictive covenant agreement between the Participant and the Company or any of its subsidiaries (which may be set forth in any Grant Instrument) or otherwise engages in activities that constitute Cause either while in Service or within a specified period of time thereafter, all Grants held by the Participant shall terminate, and the Company may rescind any exercise of an Option or SAR and the vesting of any other Grant and delivery of shares upon such exercise or vesting (including pursuant to dividends and Dividend Equivalents), as applicable on such terms as the Committee shall determine, including the right to require that in the event of any such rescission, (i) the Participant shall return to the Company the shares received upon the exercise of any Option or SAR and/or the vesting and payment of any other Grant (including pursuant to dividends and Dividend Equivalents) or, (ii) if the Participant no longer owns the shares, the Participant shall pay to the Company the amount of any gain realized or payment received as a result of any sale or other disposition of the shares (or, in the event the Participant transfers the shares by gift or otherwise without consideration, the Fair Market Value of the shares on the date of the breach of the restrictive covenant agreement (including a Participant’s Grant Instrument containing restrictive covenants) or activity constituting Cause), net of the price originally paid by the Participant for the shares. Payment by the Participant shall be made in such manner and on such terms and conditions as may be required by the Committee. The Company and its subsidiaries shall be entitled to set off against the amount of any such payment any amounts otherwise owed to the Participant by the Company or any of its subsidiaries. In addition, all Grants under the Plan shall be subject to any applicable clawback or recoupment policies, share trading policies and other policies that may be implemented by the Board from time to time.

 

(i) Governing Law; Jurisdiction. The validity, construction, interpretation and effect of the Plan and Grant Instruments issued under the Plan shall be governed and construed by and determined in accordance with the laws of the State of Florida, without giving effect to the conflict of laws provisions thereof. Any action arising out of, or relating to, any of the provisions of the Plan and Grants made hereunder shall be brought only in the United States District Court for the Southern District of Florida, or if such court does not have jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in Florida, and the jurisdiction of such court in any such proceeding shall be exclusive.

 

 

A-16

Table of Contents

 

APPENDIX B

 

 ARTICLES OF AMENDMENT

 

TO THE ARTICLES OF INCORPORATION OF

 

TOMI ENVIRONMENTAL SOLUTIONS, INC.

 

Pursuant to Section 607.1006 of the Florida Business Corporation Act, TOMI Environmental Solutions, Inc., a Florida corporation (the “Company”), hereby adopts the following amendments to its Articles of Incorporation, as amended on September 19, 2011, October 30, 2019, September 10, 2020, and July 20, 2026 (the “Articles of Incorporation”):

 

 

1.

Amendment to Article IV — Shares.

 

Article IV of the Articles of Incorporation is hereby amended and restated in its entirety as follows:

 

“ARTICLE IV — SHARES

 

The Company is authorized to issue the following shares of capital stock:

 

(a) Common Stock. 250,000,000 shares of common stock, par value $0.01 per share (the “Common Stock”).

 

(b) Series A Preferred Stock. 1,000,000 shares of cumulative, convertible Series A Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”). The Series A Preferred Stock is convertible into shares of Common Stock at a conversion ratio of one (1) share of Series A Preferred Stock for one (1) share of Common Stock. The Series A Preferred Stock has no dividend attached.

 

(c) Series B Preferred Stock. 4,000 shares of Series B Preferred Stock (the “Series B Preferred Stock.”) The Series B Preferred Stock shall be convertible at an exchange rate of 200 shares of Common Stock for each share of Series B Preferred Stock and have a stated value per share of $1,000. The Series B Preferred Stock shall carry a cumulative dividend of 7.5% per annum and shall be senior in liquidation preference to the Common Stock and equal in liquidation preference to all other authorized class of preferred stock. The dividend is payable in-kind, at the election of the Company.

 

(d) Undesignated Preferred Stock. 10,000,000 additional shares of preferred stock (the “Undesignated Preferred Stock”). The Board of Directors of the Company is authorized, subject to applicable law, to issue such shares in one or more series and to determine by resolution the designation, number of shares, voting powers, preferences, limitations and relative rights of each series, including dividend, liquidation, redemption and conversion rights, without further shareholder approval, and to file the corresponding articles of amendment pursuant to Section 607.0602 of the Florida Business Corporation Act.

 

The rights of the Series A Preferred Stock and Series B Preferred Stock existing immediately prior to the effectiveness of this amendment shall remain unchanged. The one-for-three reverse stock split of the Common Stock and Series A Preferred Stock effected on July 20, 2026, including its treatment of fractional shares, shall remain effective and is not modified or repeated by this amendment.”

 

 

2.

Amendment to Add Article VIII — Quorum.

 

The Articles of Incorporation are hereby amended by adding the following new Article VIII:

 

 
B-1

Table of Contents

 

“ARTICLE VIII — QUORUM

 

The Board of Directors may establish and modify from time to time, by amendment to the Bylaws, the quorum requirements for meetings of shareholders, provided that such requirements shall not be less than the minimum requirements prescribed by applicable law and shall otherwise comply with the rules of any securities exchange on which the Company’s securities are listed. Unless otherwise established by the Board of Directors, the existing quorum requirements shall continue to apply.”

 

 

3.

Approval. The amendments set forth in Sections 1 and 2 were approved by the Board of Directors on November [●], 2026, and separately approved by the shareholders at the Company’s Annual Meeting of Shareholders held on December 18, 2026, by the requisite votes under applicable law and the Articles of Incorporation.

 

 

 

 

4.

Effectiveness. These Articles of Amendment shall become effective upon filing with the Florida Department of State.

 

IN WITNESS WHEREOF, the undersigned has executed these Articles of Amendment as of [●], 2026.

 

TOMI ENVIRONMENTAL SOLUTIONS, INC.

 

a Florida corporation

 

 

By:

 

 

 

 

 

Name:

Halden S. Shane

 

 

 

Title:

Chief Executive Officer and Chairman of the Board

 

 

 
B-2

 

Keep reading